Modified human igm constant regions for modulation of complement-dependent cytolysis effector function

ABSTRACT

The disclosure provides modified human IgM heavy chain constant regions that include one or more amino acid substitutions, e.g., in the Cμ3 domain, where a modified human IgM antibody comprising the modified IgM constant region and a heavy chain variable region specific for a target antigen exhibits reduced complement-dependent cytotoxicity (CDC) of cells expressing the target antigen relative to a corresponding wild-type human IgM antibody.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.16/500,292, filed Oct. 2, 2019, which is a US National Stage Entry ofPCT Application No. PCT/US2018/026474, filed Apr. 6, 2018, which claimsthe benefit of U.S. Provisional Patent Application Ser. No. 62/483,087,filed Apr. 7, 2017, which are all hereby incorporated by reference intheir entireties.

REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY

The instant application contains a Sequence Listing which has beensubmitted electronically in ASCII format and is hereby incorporated byreference in its entirety. Said ASCII copy, created on Apr. 27, 2022, isnamed 010US2-Sequence-Listing and is 89,958 bytes in size.

BACKGROUND

Complement dependent cytotoxicity is an effector function used byantibodies to engage components of the innate immune system to destroyinvading microbes. Therapeutic antibodies can use the complement systemto engage the complement system to attack cells targeted by theantibody, for example, tumor cells. The complement cascade is triggeredby binding of the first component C1q to the Fc region of IgG's or tothe Fc Mu region of IgM's. Hexamerization of antibodies results information of the hexameric C1q complex that further triggers downstreamcomplement components and ends in formation of the membrane attackcomplex (MAC), which causes cell death by perforation of the cellmembrane and resulting osmotic shock. Antibodies of the IgM isotype aremultimeric (pentamers and hexamers) and are particularly well suited tobinding and multimerization of C1q. Indeed, IgM antibodies can fixcomplement between 30 to 100 times better than corresponding IgGantibodies.

For those indications where an IgM antibody is used to multimerize acell surface receptor to affect downstream signaling, however, it is notalways desirable to retain this powerful complement fixation ability.For example, IgM antibodies could be used to activate T-cells byengaging TNF receptor superfamily members like CD40, OX40 or GITR. Ineach case, multimerization driven downstream signaling can be used tocause powerful agonist activity and proliferation of T-cells. However,if the complement fixation activity of IgM antibody is left intact, itcould potentially counteract the agonist activity of IgM antibody onthese targets. For this reason, there is a need in the art to identifymutations of the IgM heavy chain constant region that could reduce oreliminate complement fixation and resultant complement dependentcytotoxicity (CDC activity).

Mutations that enhance or reduce CDC activity in mouse IgM have beenidentified. See, e.g., Arya, S., et al., J. Immunol. 152: 1206-1212(1994), Wright, J, F., et al., J. Biol. Chem. 263:11221-11226 (1988),and Wright, J. F., et al., J. Biol. Chem. 265:10506-10513 (1989). Thereremains a need in the art to identify and characterize modified humanIgM antibodies with modified CDC activity.

SUMMARY

This disclosure provides a modified human IgM constant region thatincludes one or more amino acid substitutions relative to a wild-typehuman IgM constant region, where at least one amino acid substitution isat a position in the Cμ3 domain ranging from T302 of SEQ ID NO: 1 toK322 of SEQ ID NO: 1, and where a modified IgM antibody that includesthe modified IgM constant region and a heavy chain variable regionspecific for a target antigen exhibits reduced complement-dependentcytotoxicity (CDC) of cells expressing the target antigen relative to acorresponding wild-type human IgM antibody.

In certain aspects, the modified human IgM constant region includes atleast one amino acid substitution is at amino acid T302, C303, T304,V305, T306, H307, T308, D309, L310, P311, S312, P313, L314, K315, Q316,T317, I318, S319, R320, P321, and/or K322 of SEQ ID NO: 1. For example,the modified human IgM constant region can include at least one aminoacid substitution is at position L310 of SEQ ID NO: 1, position P311 ofSEQ ID NO: 1, position P313 of SEQ ID NO: 1, position K315 of SEQ ID NO:1, or any combination thereof.

In certain aspects at least one amino acid substitution can be atposition L310 of SEQ ID NO: 1, e.g., L310 of SEQ ID NO: 1 can besubstituted with alanine (L310A), serine (L310S), aspartic acid (L310D)or glycine (L310G). In certain aspects L310 of SEQ ID NO: 1 can besubstituted with alanine (L310A), for example, the modified IgM constantregion can include SEQ ID NO: 15. In certain aspects L310 of SEQ ID NO:1 can be substituted with aspartic acid (L310D), for example, themodified IgM constant region can include SEQ ID NO: 23.

In certain aspects at least one amino acid substitution can be atposition P311 of SEQ ID NO: 1, e.g., P311 of SEQ ID NO: 1 can besubstituted with alanine (P311A), serine (P311S), or glycine (P311G). Incertain aspects P311 of SEQ ID NO: 1 can be substituted with alanine(P311A), for example, the modified IgM constant region can include SEQID NO: 2.

In certain aspects at least one amino acid substitution can be atposition P313 of SEQ ID NO: 1, e.g., P313 of SEQ ID NO: 1 can besubstituted with alanine (P313A), serine (P313S), or glycine (P313G). Incertain aspects P313 of SEQ ID NO: 1 can be substituted with serine(P313S), for example the modified IgM constant region can include SEQ IDNO: 3.

In certain aspects at least one amino acid substitution can be atposition K315 of SEQ ID NO: 1, e.g., K315 of SEQ ID NO: 1 can besubstituted with alanine (K315A), serine (K315S), aspartic acid (K315D),glutamine (K315Q), or glycine (P313G). In certain aspects K315 of SEQ IDNO: 1 can be substituted with alanine (K315A), for example the modifiedIgM constant region can include SEQ ID NO: 16. In certain aspects K315of SEQ ID NO: 1 can be substituted with aspartic acid (K315D), forexample the modified IgM constant region can include SEQ ID NO: 24. Incertain aspects K315 of SEQ ID NO: 1 can be substituted with glutamine(K315Q), for example the modified IgM constant region can include SEQ IDNO: 25.

In certain aspects the modified human IgM constant region as providedherein can include two or more amino acid substitutions. For example,the modified human IgM constant region as provided herein can includeamino acid substitutions at two or more of positions L310, P311, P313,or K315 of SEQ ID NO: 1.

In certain aspects, the modified human IgM constant region as providedherein can include amino acid substitutions at positions P311 and P313of SEQ ID NO: 1. For example, P311 of SEQ ID NO: 1 can be substitutedwith alanine (P311A), serine (P311S), or glycine (P311G), and P313 ofSEQ ID NO: 1 can be substituted with alanine (P313A), serine (P313S), orglycine (P313G). In certain aspects, P311 of SEQ ID NO: 1 can besubstituted with alanine (P311A) and P313 of SEQ ID NO: 1 can besubstituted with serine (P313S), for example the modified IgM constantregion can include SEQ ID NO: 4.

In certain aspects, the modified human IgM constant region as providedherein can include amino acid substitutions at positions L310 and K315of SEQ ID NO: 1. For example, L310 can be substituted with alanine(L310A) or serine (L310S) and K315 can be substituted with alanine(K315A) or serine (K315S), for example the modified IgM constant regioncan include SEQ ID NO: 17 or SEQ ID NO: 18.

In certain aspects, the modified human IgM constant region as providedherein can include amino acid substitutions at positions L310 and P311of SEQ ID NO: 1. For example, L310 can be substituted with alanine(L310A) and P311 can be substituted with alanine (P311A), for examplethe modified IgM constant region can include SEQ ID NO: 19.

In certain aspects, the modified human IgM constant region as providedherein can include amino acid substitutions at positions L310 and P313of SEQ ID NO: 1. For example, L310 can be substituted with alanine(L310A) and P313 can be substituted with serine (P313S), for example themodified IgM constant region can include SEQ ID NO: 20.

In certain aspects, the modified human IgM constant region as providedherein can include amino acid substitutions at positions P311 and K315of SEQ ID NO: 1. For example, P311 can be substituted with alanine(P311A) and K315 can be substituted with alanine (K315A), for examplethe modified IgM constant region can include SEQ ID NO: 21.

In certain aspects, the modified human IgM constant region as providedherein can include amino acid substitutions at positions P313 and K315of SEQ ID NO: 1. For example, P313 can be substituted with serine(P313S) and K315 can be substituted with alanine (K315A), for examplethe modified IgM constant region can include SEQ ID NO: 22.

In certain aspects, the maximum CDC activity achieved in a dose responseassay by a target-specific IgM antibody that includes the modified humanIgM constant region as provided herein is reduced by at least 5%, 10%,20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100% relative to acorresponding wild-type IgM antibody identical except for the modifiedhuman IgM constant region.

In certain aspects, the antibody concentration effecting 50% CDCactivity (EC₅₀) of a target-specific IgM antibody that includes themodified human IgM constant region as provided herein is increased by atleast 2-fold, at least 5-fold, at least 10-fold, at least 20-fold, andleast 30-fold, at least 40-fold, at least 50-fold, at least 60-fold, atleast 70-fold, at least 80-fold, at least 90-fold, or at least 100-foldrelative to a corresponding wild-type IgM antibody identical except forthe modified human IgM constant region.

The disclosure further provides a modified human IgM antibody thatincludes the modified human IgM constant region as provided herein andfurther includes a heavy chain variable region (VH) situated aminoterminal to the modified human IgM constant region, where the modifiedhuman IgM antibody specifically binds to a target antigen and exhibitsreduced complement-dependent cytotoxicity (CDC) of cells expressing thetarget antigen relative to a corresponding wild-type human IgM antibody.In certain aspects, the modified human IgM antibody can be a pentamericor a hexameric antibody that includes five or six bivalent IgM bindingunits, respectively, where each binding unit includes two IgM heavychains each including a VH situated amino terminal to the modified humanIgM constant region, and two immunoglobulin light chains each includinga light chain variable domain (VL) situated amino terminal to a humanimmunoglobulin light chain constant region. In certain aspects, themodified human IgM antibody as provided herein can be pentameric,further including a J-chain, or functional fragment thereof, or afunctional variant thereof. In certain aspects the J-chain can includeamino acids 23 to 158 of SEQ ID NO: 7 or functional fragment thereof, ora functional variant thereof. In certain aspects the J-chain or fragmentor variant thereof can be a modified J-chain that further includes aheterologous polypeptide, where the heterologous polypeptide is directlyor indirectly fused to the J-chain or fragment or variant thereof. Incertain aspects the heterologous polypeptide can be fused to the J-chainor fragment thereof via a peptide linker, e.g., a peptide linkerincludes at least 5 amino acids, but no more than 25 amino acids. Incertain aspects the peptide linker can comprise, consist essentially of,or consist of GGGGSGGGGSGGGGS (SEQ ID NO: 12). In certain aspects, theheterologous polypeptide can be fused to the N-terminus of the J-chainor fragment or variant thereof, the C-terminus of the J-chain orfragment or variant thereof, or to both the N-terminus and C-terminus ofthe J-chain or fragment or variant thereof. In certain aspects, theheterologous polypeptide can include a binding domain, e.g., an antibodyor antigen-binding fragment thereof, e.g., an Fab fragment, an Fab′fragment, an F(ab′)2 fragment, an Fd fragment, an Fv fragment, asingle-chain Fv (scFv) fragment, a disulfide-linked Fv (sdFv) fragment,or any combination thereof. In certain aspects the modified J-chain caninclude a scFv fragment. In certain aspects, the heterologouspolypeptide can specifically bind to CD3ε. In certain aspects, themodified J-chain can include the amino acid sequence SEQ ID NO: 9 (V15J)or SEQ ID NO: 11 (J15V). In certain aspects the modified J-chain canfurther include a signal peptide, e.g., the modified J-chain can includethe amino acid sequence SEQ ID NO: 8 (V15J) or SEQ ID NO: 10 (J15V). Incertain aspects the modified human IgM antibody as provided herein candirect T-cell-mediated killing of a cell expressing the target antigenat an activity level equivalent to that of a corresponding IgM antibodythat is identical to the modified IgM antibody except for the modifiedIgM constant region. In certain aspects, the cell expressing the targetantigen is a eukaryotic cell.

This disclosure further provides a polynucleotide that includes anucleic acid sequence that encodes the modified human IgM constantregion as provided herein, or a heavy chain polypeptide subunit of themodified human IgM antibody as provided herein. Also provided is acomposition that includes the provided polynucleotide. In certainaspects the composition further includes a nucleic acid sequence thatencodes a light chain polypeptide subunit. In certain aspects, the lightchain polypeptide subunit includes a human antibody light chain constantregion or fragment thereof fused to the C-terminal end of a VL. Incertain aspects the nucleic acid sequence encoding the heavy chainpolypeptide subunit and the nucleic acid sequence encoding the lightchain polypeptide subunit can be on separate vectors. In certainaspects, the nucleic acid sequence encoding the heavy chain polypeptidesubunit and the nucleic acid sequence encoding the light chainpolypeptide subunit can be on a single vector. In certain aspects, thecomposition further includes a nucleic acid sequence that encodes aJ-chain, or functional fragment thereof, or a functional variantthereof. In certain aspects, the J-chain or fragment or variant thereofis a modified J-chain that further includes a heterologous polypeptide,where the heterologous polypeptide is directly or indirectly fused tothe J-chain or fragment thereof. In certain aspects, the nucleic acidsequence encoding the heavy chain polypeptide subunit, the nucleic acidsequence encoding the light chain polypeptide subunit, and the nucleicacid sequence encoding the J-chain can be on a single vector. In certainaspects, the nucleic acid sequence encoding the heavy chain polypeptidesubunit, the nucleic acid sequence encoding the light chain polypeptidesubunit, and the nucleic acid sequence encoding the J-chain can be eachon separate vectors. All such vector or vectors are further provided bythis disclosure. The disclosure further provides a host cell thatincludes the provided polynucleotides, compositions, vector, or vectors.In certain aspects, the host cell can express the modified human IgMconstant region as provided herein, or the modified human IgM antibodyas provided herein, or any functional fragment thereof. The disclosurefurther provides a method of producing the modified human IgM constantregion as provided herein or the modified human IgM antibody as providedherein, where the method includes culturing the provided host cell, andrecovering the constant region or antibody.

BRIEF DESCRIPTION OF THE DRAWINGS/FIGURES

FIG. 1 shows an SDS PAGE gel run under non-reducing conditions to showassembly of pentamers and hexamers. Gel patterns are depicted for thecontrols, IgM (pure), IgM+J (pure), and supernatant preparations (allwithout J chain) of IgM, and the IgM mutants, S283N, P313S, P311A, andD294G.

FIG. 2 shows percent complement dependent cytolysis (CDC) activityfor 1) control anti-CD20 antibodies tested in the absence of complement(1.5.3 IgG and 1.5.3 IgM×V15J); 2) for control IgM (1.5.3 IgM, withoutJ-chain) tested in the presence of complement; and 3) for corresponding1.5.3 IgM mutants P311A, P313S, D294G, and S283N, all without J-chain,tested in the presence of complement.

FIG. 3 shows percent CDC activity for anti-CD20×anti-CD3 bispecific IgMantibodies with an anti-CD3 modified J-chain including the control 1.5.3IgM×V15J antibody, and corresponding 1.5.3 IgM×V15J mutants, P311A,P313S, D294G, and S283N.

FIG. 4 shows a T cell activation assay for a control anti-CD20 IgMlacking the anti-CD3 modified J-chain, and bispecific IgM antibodiesthat contain the anti-CD3 modified J-chain (V15J) including the controlantibody, 1.5.3 IgM×V15J, and the corresponding 1.5.3×V15J IgM mutants,D294G, S283N, P313S, and P311A.

FIG. 5 shows hybrid and reducing gels for 1.5.3 IgM×V15J, and thecorresponding 1.5.3×V15J IgM mutants, P311A, P313S, and the doublemutant P311A/P313S. The double mutant is expressed and assembled as wellas each of the single mutants.

FIG. 6 shows CDC activity for 1.5.3 IgM×V15J, and the corresponding1.5.3×V15J IgM mutants, P311A, P313S, and the double mutant P311A/P313S.The double mutant shows complete elimination of CDC activity.

FIG. 7 shows a T cell activation assay for 1.5.3 IgM×V15J, and thecorresponding 1.5.3×V15J IgM mutants, P311A, P313S, and the doublemutant P311A/P313S. The double mutant is as effective at activatingT-cells as each of the single mutants.

FIG. 8 shows CDC activity for 1.5.3 IgM without J-chain, 1.5.3 IgM×V15J,the corresponding 1.5.3×V15J IgM mutants, P311A, P313S, L310A, K315A,and the double mutant P311A/P313S. The double mutant shows completeelimination of CDC activity. Figure discloses SEQ ID NO: 41.

FIG. 9A shows CDC activity for 1.5.3 IgM without J-chain, 1.5.3IgM×V15J, the 1.5.3×V15J IgM mutants L310D and L310A, and the doublemutant P311A/P313S.

FIG. 9B shows CDC activity for 1.5.3 IgM without J-chain, 1.5.3IgM×V15J, and the 1.5.3×V15J IgM mutants K315D, K315Q, and K315A.

DETAILED DESCRIPTION Definitions

The term “a” or “an” entity refers to one or more of that entity; forexample, “a binding molecule,” is understood to represent one or morebinding molecules. As such, the terms “a” (or “an”), “one or more,” and“at least one” can be used interchangeably herein.

Furthermore, “and/or” where used herein is to be taken as specificdisclosure of each of the two specified features or components with orwithout the other. Thus, the term and/or” as used in a phrase such as “Aand/or B” herein is intended to include “A and B,” “A or B,” “A”(alone), and “B” (alone). Likewise, the term “and/or” as used in aphrase such as “A, B, and/or C” is intended to encompass each of thefollowing embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C;A and C; A and B; B and C; A (alone); B (alone); and C (alone).

Unless defined otherwise, technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this disclosure is related. For example, the ConciseDictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed.,2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed.,1999, Academic Press; and the Oxford Dictionary of Biochemistry andMolecular Biology, Revised, 2000, Oxford University Press, provide oneof skill with a general dictionary of many of the terms used in thisdisclosure.

Units, prefixes, and symbols are denoted in their Systeme Internationalde Unites (SI) accepted form. Numeric ranges are inclusive of thenumbers defining the range. Unless otherwise indicated, amino acidsequences are written left to right in amino to carboxy orientation. Theheadings provided herein are not limitations of the various aspects oraspects of the disclosure, which can be had by reference to thespecification as a whole. Accordingly, the terms defined immediatelybelow are more fully defined by reference to the specification in itsentirety.

As used herein, the term “polypeptide” is intended to encompass asingular “polypeptide” as well as plural “polypeptides,” and refers to amolecule composed of monomers (amino acids) linearly linked by amidebonds (also known as peptide bonds). The term “polypeptide” refers toany chain or chains of two or more amino acids and does not refer to aspecific length of the product. Thus, peptides, dipeptides, tripeptides,oligopeptides, “protein,” “amino acid chain,” or any other term used torefer to a chain or chains of two or more amino acids are includedwithin the definition of “polypeptide,” and the term “polypeptide” canbe used instead of, or interchangeably with any of these terms. The term“polypeptide” is also intended to refer to the products ofpost-expression modifications of the polypeptide, including withoutlimitation glycosylation, acetylation, phosphorylation, amidation, andderivatization by known protecting/blocking groups, proteolyticcleavage, or modification by non-naturally occurring amino acids. Apolypeptide can be derived from a biological source or produced byrecombinant technology but is not necessarily translated from adesignated nucleic acid sequence. It can be generated in any manner,including by chemical synthesis.

A polypeptide as disclosed herein can be of a size of about 3 or more, 5or more, 10 or more, 20 or more, 25 or more, 50 or more, 75 or more, 100or more, 200 or more, 500 or more, 1,000 or more, or 2,000 or more aminoacids. Polypeptides can have a defined three-dimensional structure,although they do not necessarily have such structure. Polypeptides witha defined three-dimensional structure are referred to as folded, andpolypeptides which do not possess a defined three-dimensional structure,but rather can adopt many different conformations, are referred to asunfolded. As used herein, the term glycoprotein refers to a proteincoupled to at least one carbohydrate moiety that is attached to theprotein via an oxygen-containing or a nitrogen-containing side chain ofan amino acid, e.g., a serine or an asparagine.

By an “isolated” polypeptide or a fragment, variant, or derivativethereof is intended a polypeptide that is not in its natural milieu. Noparticular level of purification is required. For example, an isolatedpolypeptide can be removed from its native or natural environment.Recombinantly produced polypeptides and proteins expressed in host cellsare considered isolated as disclosed herein, as are native orrecombinant polypeptides which have been separated, fractionated, orpartially or substantially purified by any suitable technique.

As used herein, the term “a non-naturally occurring polypeptide” or anygrammatical variants thereof, is a conditional definition thatexplicitly excludes, but only excludes, those forms of the polypeptidethat are, or could be, determined or interpreted by a judge or anadministrative or judicial body, to be “naturally-occurring.”

Other polypeptides disclosed herein are fragments, derivatives, analogs,or variants of the foregoing polypeptides, and any combination thereof.The terms “fragment,” “variant,” “derivative” and “analog” as disclosedherein include any polypeptides which retain at least some of theproperties of the corresponding native antibody or polypeptide, forexample, specifically binding to an antigen. Fragments of polypeptidesinclude, for example, proteolytic fragments, as well as deletionfragments, in addition to specific antibody fragments discussedelsewhere herein. Variants of, e.g., a polypeptide include fragments asdescribed above, and also polypeptides with altered amino acid sequencesdue to amino acid substitutions, deletions, or insertions. In certainaspects, variants can be non-naturally occurring. Non-naturallyoccurring variants can be produced using art-known mutagenesistechniques. Variant polypeptides can comprise conservative ornon-conservative amino acid substitutions, deletions or additions.Derivatives are polypeptides that have been altered to exhibitadditional features not found on the original polypeptide. Examplesinclude fusion proteins. Variant polypeptides can also be referred toherein as “polypeptide analogs.” As used herein a “derivative” of apolypeptide can also refer to a subject polypeptide having one or moreamino acids chemically derivatized by reaction of a functional sidegroup. Also included as “derivatives” are those peptides that containone or more derivatives of the twenty standard amino acids. For example,4-hydroxyproline can be substituted for proline; 5-hydroxylysine can besubstituted for lysine; 3-methylhistidine can be substituted forhistidine; homoserine can be substituted for serine; and ornithine canbe substituted for lysine.

A “conservative amino acid substitution” is one in which one amino acidis replaced with another amino acid having a similar side chain.Families of amino acids having similar side chains have been defined inthe art, including basic side chains (e.g., lysine, arginine,histidine), acidic side chains (e.g., aspartic acid, glutamic acid),uncharged polar side chains (e.g., asparagine, glutamine, serine,threonine, tyrosine, cysteine), nonpolar side chains (e.g., glycine,alanine, valine, leucine, isoleucine, proline, phenylalanine,methionine, tryptophan), beta-branched side chains (e.g., threonine,valine, isoleucine) and aromatic side chains (e.g., tyrosine,phenylalanine, tryptophan, histidine). For example, substitution of aphenylalanine for a tyrosine is a conservative substitution. In certainembodiments, conservative substitutions in the sequences of thepolypeptides and antibodies of the present disclosure do not abrogatethe binding of the polypeptide or antibody containing the amino acidsequence, to the antigen to which the binding molecule binds. Methods ofidentifying nucleotide and amino acid conservative substitutions whichdo not eliminate antigen-binding are well-known in the art (see, e.g.,Brummell et al., Biochem. 32: 1180-1 187 (1993); Kobayashi et al.,Protein Eng. 12(10):879-884 (1999); and Burks et al., Proc. Natl. Acad.Sci. USA 94:.412-417 (1997)).

The term “polynucleotide” is intended to encompass a singular nucleicacid as well as plural nucleic acids, and refers to an isolated nucleicacid molecule or construct, e.g., messenger RNA (mRNA), cDNA, or plasmidDNA (pDNA). A polynucleotide can comprise a conventional phosphodiesterbond or a non-conventional bond (e.g., an amide bond, such as found inpeptide nucleic acids (PNA)). The terms “nucleic acid” or “nucleic acidsequence” refer to any one or more nucleic acid segments, e.g., DNA orRNA fragments, present in a polynucleotide.

By an “isolated” nucleic acid or polynucleotide is intended any form ofthe nucleic acid or polynucleotide that is separated from its nativeenvironment. For example, gel-purified polynucleotide, or a recombinantpolynucleotide encoding a polypeptide contained in a vector would beconsidered to be “isolated.” Also, a polynucleotide segment, e.g., a PCRproduct, which has been engineered to have restriction sites for cloningis considered to be “isolated.” Further examples of an isolatedpolynucleotide include recombinant polynucleotides maintained inheterologous host cells or purified (partially or substantially)polynucleotides in a non-native solution such as a buffer or saline.Isolated RNA molecules include in vivo or in vitro RNA transcripts ofpolynucleotides, where the transcript is not one that would be found innature. Isolated polynucleotides or nucleic acids further include suchmolecules produced synthetically. In addition, polynucleotide or anucleic acid can be or can include a regulatory element such as apromoter, ribosome binding site, or a transcription terminator.

As used herein, the term “a non-naturally occurring polynucleotide” orany grammatical variants thereof, is a conditional definition thatexplicitly excludes, but only excludes, those forms of the nucleic acidor polynucleotide that are, or could be, determined or interpreted by ajudge, or an administrative or judicial body, to be“naturally-occurring.”

As used herein, a “coding region” is a portion of nucleic acid whichconsists of codons translated into amino acids. Although a “stop codon”(TAG, TGA, or TAA) is not translated into an amino acid, it can beconsidered to be part of a coding region, but any flanking sequences,for example promoters, ribosome binding sites, transcriptionalterminators, introns, and the like, are not part of a coding region. Twoor more coding regions can be present in a single polynucleotideconstruct, e.g., on a single vector, or in separate polynucleotideconstructs, e.g., on separate (different) vectors. Furthermore, anyvector can contain a single coding region, or can comprise two or morecoding regions, e.g., a single vector can separately encode animmunoglobulin heavy chain variable region and an immunoglobulin lightchain variable region. In addition, a vector, polynucleotide, or nucleicacid can include heterologous coding regions, either fused or unfused toanother coding region. Heterologous coding regions include withoutlimitation, those encoding specialized elements or motifs, such as asecretory signal peptide or a heterologous functional domain.

In certain embodiments, the polynucleotide or nucleic acid is DNA. Inthe case of DNA, a polynucleotide comprising a nucleic acid whichencodes a polypeptide normally can include a promoter and/or othertranscription or translation control elements operably associated withone or more coding regions. An operable association is when a codingregion for a gene product, e.g., a polypeptide, is associated with oneor more regulatory sequences in such a way as to place expression of thegene product under the influence or control of the regulatorysequence(s). Two DNA fragments (such as a polypeptide coding region anda promoter associated therewith) are “operably associated” if inductionof promoter function results in the transcription of mRNA encoding thedesired gene product and if the nature of the linkage between the twoDNA fragments does not interfere with the ability of the expressionregulatory sequences to direct the expression of the gene product orinterfere with the ability of the DNA template to be transcribed. Thus,a promoter region would be operably associated with a nucleic acidencoding a polypeptide if the promoter was capable of effectingtranscription of that nucleic acid. The promoter can be a cell-specificpromoter that directs substantial transcription of the DNA inpredetermined cells. Other transcription control elements, besides apromoter, for example enhancers, operators, repressors, andtranscription termination signals, can be operably associated with thepolynucleotide to direct cell-specific transcription.

A variety of transcription control regions are known to those skilled inthe art. These include, without limitation, transcription controlregions which function in vertebrate cells, such as, but not limited to,promoter and enhancer segments from cytomegaloviruses (the immediateearly promoter, in conjunction with intron-A), simian virus 40 (theearly promoter), and retroviruses (such as Rous sarcoma virus). Othertranscription control regions include those derived from vertebrategenes such as actin, heat shock protein, bovine growth hormone andrabbit β-globin, as well as other sequences capable of controlling geneexpression in eukaryotic cells. Additional suitable transcriptioncontrol regions include tissue-specific promoters and enhancers as wellas lymphokine-inducible promoters (e.g., promoters inducible byinterferons or interleukins).

Similarly, a variety of translation control elements are known to thoseof ordinary skill in the art. These include, but are not limited toribosome binding sites, translation initiation and termination codons,and elements derived from picornaviruses (particularly an internalribosome entry site, or IRES, also referred to as a CITE sequence).

In other embodiments, a polynucleotide can be RNA, for example, in theform of messenger RNA (mRNA), transfer RNA, or ribosomal RNA.

Polynucleotide and nucleic acid coding regions can be associated withadditional coding regions which encode secretory or signal peptides,which direct the secretion of a polypeptide encoded by a polynucleotideas disclosed herein. According to the signal hypothesis, proteinssecreted by mammalian cells have a signal peptide or secretory leadersequence which is cleaved from the mature protein once export of thegrowing protein chain across the rough endoplasmic reticulum has beeninitiated. Those of ordinary skill in the art are aware thatpolypeptides secreted by vertebrate cells can have a signal peptidefused to the N-terminus of the polypeptide, which is cleaved from thecomplete or “full length” polypeptide to produce a secreted or “mature”form of the polypeptide. In certain embodiments, the native signalpeptide, e.g., an immunoglobulin heavy chain or light chain signalpeptide is used, or a functional derivative of that sequence thatretains the ability to direct the secretion of the polypeptide that isoperably associated with it. Alternatively, a heterologous mammaliansignal peptide, or a functional derivative thereof, can be used. Forexample, the wild-type leader sequence can be substituted with theleader sequence of human tissue plasminogen activator (TPA) or mouseβ-glucuronidase.

As used herein, the term “CD20” refers to a membrane protein expressedon the surface of B lymphocytes. The CD20 protein is referred to in theliterature by other names, e.g., B-lymphocyte antigen CD20, B-lymphocytecell-surface antigen B1, Bp35, CVID5, LEU-16, Membrane-spanning4-domains subfamily A member 1, or MS4A2. Certain multivalent anti-CD20binding molecules, e.g., IgM antibodies or fragments thereof asdisclosed herein are further described in PCT Publication No.WO/2016/141303, which is incorporated herein by reference in itsentirety.

Disclosed herein are certain binding molecules, or antigen-bindingfragments, variants, or derivatives thereof. Unless specificallyreferring to full-sized antibodies, the term “binding molecule” includesfull-sized antibodies as well as antigen-binding subunits, fragments,variants, analogs, or derivatives of such antibodies, e.g., engineeredantibody molecules or fragments that bind antigen in a manner similar toantibody molecules, but which use a different scaffold.

As used herein, the term “binding molecule” refers in its broadest senseto a molecule that specifically binds to a target or moleculardeterminant, e.g., an epitope or an antigenic determinant. As describedfurther herein, a binding molecule can comprise one or more “antigenbinding domains” described herein. A non-limiting example of a bindingmolecule is an antibody or fragment thereof that retainsantigen-specific binding.

As used herein, the terms “binding domain” or “antigen binding domain”refer to a region of a binding molecule that is sufficient tospecifically bind to an epitope. For example, an “Fv,” e.g., a variableheavy chain and variable light chain of an antibody, either as twoseparate polypeptide subunits or as a single chain, is considered to bea “binding domain.” Other antigen binding domains include, withoutlimitation, the variable heavy chain (VHH) of an antibody derived from acamelid species, or six immunoglobulin complementarity determiningregions (CDRs) expressed in a fibronectin scaffold. A “binding molecule”as described herein can include one, two, three, four, five, six, seven,eight, nine, ten, eleven, twelve or more “antigen binding domains.”

The terms “antibody” and “immunoglobulin” can be used interchangeablyherein. An antibody (or a fragment, variant, or derivative thereof asdisclosed herein) includes at least the variable domain of a heavy chain(for camelid species) or at least the variable domains of a heavy chainand a light chain. Basic immunoglobulin structures in vertebrate systemsare relatively well understood. (See, e.g., Harlow et al., Antibodies: ALaboratory Manual, Cold Spring Harbor Laboratory Press, 2nd ed. 1988).Unless otherwise stated, the term “antibody” encompasses anythingranging from a small antigen-binding fragment of an antibody to a fullsized antibody, e.g., an IgG antibody that includes two complete heavychains and two complete light chains, an IgA antibody that includes fourcomplete heavy chains and four complete light chains and can include aJ-chain and/or a secretory component, or an IgM antibody that includesten or twelve complete heavy chains and ten or twelve complete lightchains and can include a J-chain.

As will be discussed in more detail below, the term “immunoglobulin”comprises various broad classes of polypeptides that can bedistinguished biochemically. Those skilled in the art will appreciatethat heavy chains are classified as gamma, mu, alpha, delta, or epsilon,(γ, μ, α, δ, ε) with some subclasses among them (e.g., γ1-γ4 or α1-α2)).It is the nature of this chain that determines the “isotype” of theantibody as IgG, IgM, IgA IgG, or IgE, respectively. The immunoglobulinsubclasses (subtypes) e.g., IgG₁, IgG₂, IgG₃, IgG₄, IgA₁, IgA₂, are wellcharacterized and are known to confer functional specialization.Modified versions of each of these immunoglobulins are readilydiscernible to the skilled artisan in view of the instant disclosureand, accordingly, are within the scope of this disclosure. In certainembodiments, this disclosure provides modified human IgM antibodies.

Light chains are classified as either kappa or lambda (κ, λ). Each heavychain class can be bound with either a kappa or lambda light chain. Ingeneral, the light and heavy chains are covalently bonded to each other,and the “tail” portions of the two heavy chains are bonded to each otherby covalent disulfide linkages or non-covalent linkages when theimmunoglobulins are expressed, e.g., by hybridomas, B cells orgenetically engineered host cells. In the heavy chain, the amino acidsequences run from an N-terminus at the forked ends of the Yconfiguration to the C-terminus at the bottom of each chain. The basicstructure of certain antibodies, e.g., IgG antibodies, includes twoheavy chain subunits and two light chain subunits covalently connectedvia disulfide bonds to form a “Y” structure, also referred to herein asan “H2L2” structure, or a “binding unit.”

The term “binding unit” is used herein to refer to the portion of abinding molecule, e.g., an antibody or antigen-binding fragment thereof,which corresponds to a standard immunoglobulin structure, e.g., twoheavy chains or fragments thereof and two light chains or fragmentsthereof, or two heavy chains or fragments thereof derived, e.g., from acamelid or condricthoid antibody. In certain aspects, e.g., where thebinding molecule is a bivalent IgG antibody or antigen-binding fragmentthereof, the terms “binding molecule” and “binding unit” are equivalent.In other aspects, e.g., where the binding molecule is an IgM pentamer oran IgM hexamer, the binding molecule comprises two or more “bindingunits,” five or six in the case of an IgM pentamer or hexamer,respectively. A binding unit need not include full-length antibody heavyand light chains, but will typically be bivalent, i.e., will include two“antigen binding domains,” as defined below. Certain IgM-derived bindingmolecules provided in this disclosure are pentameric or hexameric andinclude five or six bivalent binding units that include IgM constantregions, e.g., modified human IgM constant regions, or fragmentsthereof. As used herein, a binding molecule comprising two or morebinding units, e.g., five or six binding units, can be referred to as“multimeric.”

The terms “J-chain,” “native sequence J-chain” or “native J-chain” asused herein refers to J-chain of native sequence IgM or IgA antibodiesof any animal species, including mature human J-chain, the amino acidsequence of which is presented as SEQ ID NO: 7.

The term “modified J-chain” is used herein to refer to variants ofnative sequence J-chain polypeptides comprising a heterologous moiety,e.g., a heterologous polypeptide, e.g., an extraneous binding domainintroduced into the native sequence. The introduction can be achieved byany means, including direct or indirect fusion of the heterologouspolypeptide or other moiety or by attachment through a peptide orchemical linker. The term “modified human J-chain” encompasses, withoutlimitation, a native sequence human J-chain of the amino acid sequenceof SEQ ID NO: 7 or functional fragment thereof modified by theintroduction of a heterologous moiety, e.g., a heterologous polypeptide,e.g., an extraneous binding domain. In certain aspects the heterologousmoiety does not interfere with efficient polymerization of IgM into apentamer and binding of such polymers to a target. Exemplary modifiedJ-chains can be found, e.g., in PCT Publication No. WO 2015/153912, inPCT Publication No. WO/2017/059387, and in PCT Publication No.WO/2017/059380, each of which is incorporated herein by reference in itsentirety.

The terms “valency,” “bivalent,” “multivalent” and grammaticalequivalents, refer to the number of antigen binding domains in givenbinding molecule or binding unit. As such, the terms “bivalent”,“tetravalent”, and “hexavalent” in reference to a given bindingmolecule, e.g., an IgM antibody or fragment thereof, denote the presenceof two antigen binding domains, four antigen binding domains, and sixantigen binding domains, respectively. In a typical IgM-derived bindingmolecule where each binding unit is bivalent, the binding moleculeitself can have 10 or 12 valencies. A bivalent or multivalent bindingmolecule can be monospecific, i.e., all of the antigen binding domainsare the same, or can be bispecific or multispecific, e.g., where two ormore antigen binding domains are different, e.g., bind to differentepitopes on the same antigen, or bind to entirely different antigens.

The term “epitope” includes any molecular determinant capable ofspecific binding to an antibody. In certain aspects, an epitope caninclude chemically active surface groupings of molecules such as aminoacids, sugar side chains, phosphoryl, or sulfonyl, and, in certainaspects, can have three-dimensional structural characteristics, and orspecific charge characteristics. An epitope is a region of a target thatis bound by an antibody.

The term “target” is used in the broadest sense to include substancesthat can be bound by a binding molecule. A target can be, e.g., apolypeptide, a nucleic acid, a carbohydrate, a lipid, or other molecule.Moreover, a “target” can, for example, be a cell, an organ, or anorganism that comprises an epitope bound that can be bound by a bindingmolecule.

Both the light and heavy chains are divided into regions of structuraland functional homology. The terms “constant” and “variable” are usedfunctionally. In this regard, it will be appreciated that the variabledomains of both the variable light (VL) and variable heavy (VH) chainportions determine antigen recognition and specificity. Conversely, theconstant regions of the light chain (CL) and the heavy chain (e.g., CH1,CH2, CH3, or CH4) confer biological properties such as secretion,transplacental mobility, Fc receptor binding, complement binding, andthe like. By convention the numbering of the constant region domainsincreases as they become more distal from the antigen binding site oramino-terminus of the antibody. The N-terminal portion is a variableregion and at the C-terminal portion is a constant region; the CH3 (orCH4 in the case of IgM) and CL domains are at the carboxy-terminus ofthe heavy and light chain, respectively.

A “full length IgM antibody heavy chain” is a polypeptide that includes,in N-terminal to C-terminal direction, an antibody heavy chain variabledomain (V_(H)), an antibody constant heavy chain constant domain 1 (CM1or Cμ1), an antibody heavy chain constant domain 2 (CM2 or Cμ2), anantibody heavy chain constant domain 3 (CM3 or Cμ3), and an antibodyheavy chain constant domain 4 (CM4 or Cμ3) that can include a tailpiece.

As indicated above, a variable region (i.e., the “antigen bindingdomain”) allows a binding molecule to selectively recognize andspecifically bind epitopes on antigens. That is, the VL domain and VHdomain (or just a VH domain for camelid or condricthoid antibodies(designated as VHH)), or subset of the complementarity determiningregions (CDRs), of a binding molecule, e.g., an antibody, can combine toform the antigen binding domain. More specifically, an antigen bindingdomain can be defined by three CDRs on each of the VH and VL chains (or3 CDRs on a VHH). Certain antibodies form larger structures. Forexample, IgM can form a dimeric, pentameric, or hexameric molecule thatincludes two, five, or six H2L2 binding units and optionally a J-chaincovalently connected via disulfide bonds.

The six “complementarity determining regions” or “CDRs” present in anantibody antigen binding domain are short, non-contiguous sequences ofamino acids that are specifically positioned to form the antigen bindingdomain as the antibody assumes its three-dimensional configuration in anaqueous environment. The remainder of the amino acids in the antigenbinding domain, referred to as “framework” regions, show lessinter-molecular variability. The framework regions largely adopt aβ-sheet conformation and the CDRs form loops which connect, and in somecases form part of, the β-sheet structure. Thus, framework regions actto form a scaffold that provides for positioning the CDRs in correctorientation by inter-chain, non-covalent interactions. The antigenbinding domain formed by the positioned CDRs defines a surfacecomplementary to the epitope on the immunoreactive antigen. Thiscomplementary surface promotes the non-covalent binding of the antibodyto its cognate epitope. The amino acids that make up the CDRs and theframework regions, respectively, can be readily identified for any givenheavy or light chain variable region by one of ordinary skill in theart, since they have been defined in various different ways (see,“Sequences of Proteins of Immunological Interest,” Kabat, E., et al.,U.S. Department of Health and Human Services, (1983); and Chothia andLesk, J. Mol. Biol., 196:901-917 (1987), which are incorporated hereinby reference in their entireties).

In the case where there are two or more definitions of a term which isused and/or accepted within the art, the definition of the term as usedherein is intended to include all such meanings unless explicitly statedto the contrary. A specific example is the use of the term“complementarity determining region” (“CDR”) to describe thenon-contiguous antigen combining sites found within the variable regionof both heavy and light chain polypeptides. These regions have beendescribed, for example, by Kabat et al., U.S. Dept. of Health and HumanServices, “Sequences of Proteins of Immunological Interest” (1983) andby Chothia et al., J. Mol. Biol. 196:901-917 (1987), which areincorporated herein by reference. The Kabat and Chothia definitionsinclude overlapping or subsets of amino acids when compared against eachother. Nevertheless, application of either definition (or otherdefinitions known to those of ordinary skill in the art) to refer to aCDR of an antibody or variant thereof is intended to be within the scopeof the term as defined and used herein, unless otherwise indicated. Theappropriate amino acids which encompass the CDRs as defined by each ofthe above cited references are set forth below in Table 1 as acomparison. The exact amino acid numbers which encompass a particularCDR will vary depending on the sequence and size of the CDR. Thoseskilled in the art can routinely determine which amino acids comprise aparticular CDR given the variable region amino acid sequence of theantibody.

TABLE 1 CDR Definitions* Kabat Chothia VH CDR1 31-35 26-32 VH CDR2 50-6552-58 VH CDR3  95-102  95-102 VL CDR1 24-34 26-32 VL CDR2 50-56 50-52 VLCDR3 89-97 91-96 *Numbering of all CDR definitions in Table 1 isaccording to the numbering conventions set forth by Kabat et al. (seebelow).

Immunoglobulin variable domains can also be analyzed, e.g., using theIMGT information system (www://imgt.cines.fr/) (IMGT®/V-Quest) toidentify variable region segments, including CDRs. See, e.g., Brochet,X. et al., Nucl. Acids Res. 36:W503-508 (2008).

Kabat et al. also defined a numbering system for variable and constantregion sequences that is applicable to any antibody. One of ordinaryskill in the art can unambiguously assign this system of “Kabatnumbering” to any variable domain sequence, without reliance on anyexperimental data beyond the sequence itself. As used herein, “Kabatnumbering” refers to the numbering system set forth by Kabat et al.,U.S. Dept. of Health and Human Services, “Sequence of Proteins ofImmunological Interest” (1983). Unless use of the Kabat numbering systemis explicitly noted, however, consecutive numbering is used for aminoacid sequences in this disclosure. Another numbering scheme is the Eunumbering system for IgG (Edelman, GM, et al., Proc. Natl. Acad. Sci.USA 63:78-85 (1969)), which has been adapted for other immunoglobulinsincluding IgM (see, e.g., Arya, S., et al., J. Immunol. 152: 1206-1212(1994)).

Binding molecules, e.g., antibodies or antigen-binding fragments,variants, or derivatives thereof include, but are not limited to,polyclonal, monoclonal, human, humanized, or chimeric antibodies, singlechain antibodies, epitope-binding fragments, e.g., Fab, Fab′ andF(ab′)₂, Fd, Fvs, single-chain Fvs (scFv), single-chain antibodies,disulfide-linked Fvs (sdFv), fragments comprising either a VL or VHdomain, fragments produced by a Fab expression library. ScFv moleculesare known in the art and are described, e.g., in U.S. Pat. No.5,892,019.

By “specifically binds,” it is generally meant that a binding molecule,e.g., an antibody or fragment, variant, or derivative thereof binds toan epitope via its antigen binding domain, and that the binding entailssome complementarity between the antigen binding domain and the epitope.According to this definition, a binding molecule is said to“specifically bind” to an epitope when it binds to that epitope, via itsantigen binding domain more readily than it would bind to a random,unrelated epitope. The term “specificity” is used herein to qualify therelative affinity by which a certain binding molecule binds to a certainepitope. For example, binding molecule “A” can be deemed to have ahigher specificity for a given epitope than binding molecule “B,” orbinding molecule “A” can be said to bind to epitope “C” with a higherspecificity than it has for related epitope “D.”

A binding molecule, e.g., an antibody or fragment, variant, orderivative thereof disclosed herein can be said to bind a target antigenwith an off rate (k(off)) of less than or equal to 5×10⁻² sec⁻¹, 10⁻²sec⁻¹, 5×10⁻³ sec⁻¹, 10⁻³ sec⁻¹, 5×10⁻⁴ sec⁻¹, 10⁻⁴ sec⁻¹, 5×10⁻⁵ sec⁻¹,or 10⁻⁵ sec⁻¹ 5×10⁻⁶ sec⁻¹, 10⁻⁶ sec⁻¹, 5×10⁻⁷ sec⁻¹ or 10⁻⁷ sec⁻¹.

A binding molecule, e.g., an antibody or antigen-binding fragment,variant, or derivative disclosed herein can be said to bind a targetantigen with an on rate (k(on)) of greater than or equal to 10³ M⁻¹sec⁻¹, 5×10³ M⁻¹ sec⁻¹, 10⁴ M⁻¹ sec⁻¹, 5×10⁴ M⁻¹ sec⁻¹, 10⁵ M⁻¹ sec⁻¹,5×10⁵ M⁻¹ sec⁻¹, 10⁶ M⁻¹ sec⁻¹, or 5×10⁶ M⁻¹ sec⁻¹ or 10⁷ M⁻¹ sec⁻¹.

A binding molecule, e.g., an antibody or fragment, variant, orderivative thereof is said to competitively inhibit binding of areference antibody or antigen binding fragment to a given epitope if itpreferentially binds to that epitope to the extent that it blocks, tosome degree, binding of the reference antibody or antigen bindingfragment to the epitope. Competitive inhibition can be determined by anymethod known in the art, for example, competition ELISA assays. Abinding molecule can be said to competitively inhibit binding of thereference antibody or antigen binding fragment to a given epitope by atleast 90%, at least 80%, at least 70%, at least 60%, or at least 50%.

As used herein, the term “affinity” refers to a measure of the strengthof the binding of an individual epitope with one or more antigen bindingdomains, e.g., of an immunoglobulin molecule. See, e.g., Harlow et al.,Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press,2nd ed. 1988) at pages 27-28. As used herein, the term “avidity” refersto the overall stability of the complex between a population of antigenbinding domains and an antigen. See, e.g., Harlow at pages 29-34.Avidity is related to both the affinity of individual antigen bindingdomains in the population with specific epitopes, and also the valenciesof the immunoglobulins and the antigen. For example, the interactionbetween a bivalent monoclonal antibody and an antigen with a highlyrepeating epitope structure, such as a polymer, would be one of highavidity. An interaction between a between a bivalent monoclonal antibodywith a receptor present at a high density on a cell surface would alsobe of high avidity.

Binding molecules or antigen-binding fragments, variants or derivativesthereof as disclosed herein can also be described or specified in termsof their cross-reactivity. As used herein, the term “cross-reactivity”refers to the ability of a binding molecule, e.g., an antibody orfragment, variant, or derivative thereof, specific for one antigen, toreact with a second antigen; a measure of relatedness between twodifferent antigenic substances. Thus, a binding molecule is crossreactive if it binds to an epitope other than the one that induced itsformation. The cross-reactive epitope generally contains many of thesame complementary structural features as the inducing epitope, and insome cases, can actually fit better than the original.

A binding molecule, e.g., an antibody or fragment, variant, orderivative thereof can also be described or specified in terms of theirbinding affinity to an antigen. For example, a binding molecule can bindto an antigen with a dissociation constant or K_(D) no greater than5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M,5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M,5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M,10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M.

Antibody fragments including single-chain antibodies or other antigenbinding domains can exist alone or in combination with one or more ofthe following: hinge region, CH1, CH2, CH3, or CH4 domains, J-chain, orsecretory component. Also included are antigen-binding fragments thatcan include any combination of variable region(s) with one or more of ahinge region, CH1, CH2, CH3, or CH4 domains, a J-chain, or a secretorycomponent. Binding molecules, e.g., antibodies, or antigen-bindingfragments thereof can be from any animal origin including birds andmammals. The antibodies can be human, murine, donkey, rabbit, goat,guinea pig, camel, llama, horse, or chicken antibodies. In anotherembodiment, the variable region can be condricthoid in origin (e.g.,from sharks). As used herein, “human” antibodies include antibodieshaving the amino acid sequence of a human immunoglobulin and includeantibodies isolated from human immunoglobulin libraries or from animalstransgenic for one or more human immunoglobulins and can in someinstances express endogenous immunoglobulins and some not, as describedinfra and, for example in, U.S. Pat. No. 5,939,598 by Kucherlapati etal.

As used herein, the term “heavy chain subunit” includes amino acidsequences derived from an immunoglobulin heavy chain, a bindingmolecule, e.g., an antibody comprising a heavy chain subunit can includeat least one of: a VH domain, a CH1 domain, a hinge (e.g., upper,middle, and/or lower hinge region) domain, a CH2 domain, a CH3 domain, aCH4 domain, or a variant or fragment thereof. For example, a bindingmolecule, e.g., an antibody or fragment, variant, or derivative thereofcan include, without limitation, in addition to a VH domain: a CH1domain; a CH1 domain, a hinge, and a CH2 domain; a CH1 domain and a CH3domain; a CH1 domain, a hinge, and a CH3 domain; or a CH1 domain, ahinge domain, a CH2 domain, and a CH3 domain. In certain aspects abinding molecule, e.g., an antibody or fragment, variant, or derivativethereof can include, in addition to a VH domain, a CH3 domain and a CH4domain; or a CH3 domain, a CH4 domain, and a J-chain. Further, a bindingmolecule for use in the disclosure can lack certain constant regionportions, e.g., all or part of a CH2 domain. It will be understood byone of ordinary skill in the art that these domains (e.g., the heavychain subunit) can be modified such that they vary in amino acidsequence from the original immunoglobulin molecule.

As used herein, the term “light chain subunit” includes amino acidsequences derived from an immunoglobulin light chain. The light chainsubunit includes at least a VL, and can further include a CL (e.g., Cκor Cλ) domain.

Binding molecules, e.g., antibodies or antigen-binding fragments,variants, or derivatives thereof can be described or specified in termsof the epitope(s) or portion(s) of an antigen that they recognize orspecifically bind. The portion of a target antigen that specificallyinteracts with the antigen binding domain of an antibody is an“epitope,” or an “antigenic determinant.” A target antigen can comprisea single epitope or at least two epitopes, and can include any number ofepitopes, depending on the size, conformation, and type of antigen.

As used herein the term “disulfide bond” includes the covalent bondformed between two sulfur atoms. The amino acid cysteine comprises athiol group that can form a disulfide bond or bridge with a second thiolgroup.

As used herein, the term “chimeric antibody” refers to an antibody inwhich the immunoreactive region or site is obtained or derived from afirst species and the constant region (which can be intact, partial ormodified) is obtained from a second species. In some embodiments thetarget binding region or site will be from a non-human source (e.g.mouse or primate) and the constant region is human.

The term “multispecific antibody, e.g., “bispecific antibody” refers toan antibody that has antigen binding domains for two or more differentepitopes within a single antibody molecule. Other binding molecules inaddition to the canonical antibody structure can be constructed with twobinding specificities. Epitope binding by bispecific or multispecificantibodies can be simultaneous or sequential. Triomas and hybridhybridomas are two examples of cell lines that can secrete bispecificantibodies. Bispecific antibodies can also be constructed by recombinantmeans. (Strohlein and Heiss, Future Oncol. 6:1387-94 (2010); Mabry andSnavely, IDrugs. 13:543-9 (2010)). A bispecific antibody can also be adiabody.

As used herein, the term “engineered antibody” refers to an antibody inwhich the variable domain and/or constant region in either the heavy andlight chain or both is altered by at least partial replacement of one ormore amino acids in the CDR, framework, and/or constant regions. Incertain aspects entire CDRs from an antibody of known specificity can begrafted into the framework regions of a heterologous antibody. Althoughalternate CDRs can be derived from an antibody of the same class or evensubclass as the antibody from which the framework regions are derived,CDRs can also be derived from an antibody of different class, e.g., froman antibody from a different species. An engineered antibody in whichone or more “donor” CDRs from a non-human antibody of known specificityare grafted into a human heavy or light chain framework region isreferred to herein as a “humanized antibody.” In certain aspects, notall of the CDRs are replaced with the complete CDRs from the donorvariable region and yet the antigen binding capacity of the donor canstill be transferred to the recipient variable domains. Given theexplanations set forth in, e.g., U.S. Pat. Nos. 5,585,089, 5,693,761,5,693,762, and 6,180,370, it will be well within the competence of thoseskilled in the art, either by carrying out routine experimentation or bytrial and error testing to obtain a functional engineered or humanizedantibody.

As used herein the term “engineered” includes manipulation of nucleicacid or polypeptide molecules by synthetic means (e.g. by recombinanttechniques, in vitro peptide synthesis, by enzymatic or chemicalcoupling of peptides or some combination of these techniques).

As used herein, the terms “linked,” “fused” or “fusion” or othergrammatical equivalents can be used interchangeably. These terms referto the joining together of two more elements or components, by whatevermeans including chemical conjugation or recombinant means. An “in-framefusion” refers to the joining of two or more polynucleotide open readingframes (ORFs) to form a continuous longer ORF, in a manner thatmaintains the translational reading frame of the original ORFs. Thus, arecombinant fusion protein is a single protein containing two or moresegments that correspond to polypeptides encoded by the original ORFs(which segments are not normally so joined in nature.) Although thereading frame is thus made continuous throughout the fused segments, thesegments can be physically or spatially separated by, for example,in-frame linker sequence. For example, polynucleotides encoding the CDRsof an immunoglobulin variable region can be fused, in-frame, but beseparated by a polynucleotide encoding at least one immunoglobulinframework region or additional CDR regions, as long as the “fused” CDRsare co-translated as part of a continuous polypeptide.

In the context of polypeptides, a “linear sequence” or a “sequence” isan order of amino acids in a polypeptide in an amino to carboxylterminal direction in which amino acids that neighbor each other in thesequence are contiguous in the primary structure of the polypeptide. Aportion of a polypeptide that is “amino-terminal” or “N-terminal” toanother portion of a polypeptide is that portion that comes earlier inthe sequential polypeptide chain. Similarly, a portion of a polypeptidethat is “carboxy-terminal” or “C-terminal” to another portion of apolypeptide is that portion that comes later in the sequentialpolypeptide chain. For example, in a typical antibody, the variabledomain is “N-terminal” to the constant region, and the constant regionis “C-terminal” to the variable domain.

The term “expression” as used herein refers to a process by which a geneproduces a biochemical, for example, a polypeptide. The process includesany manifestation of the functional presence of the gene within the cellincluding, without limitation, gene knockdown as well as both transientexpression and stable expression. It includes without limitationtranscription of the gene into RNA, e.g., messenger RNA (mRNA), and thetranslation of such mRNA into polypeptide(s). If the final desiredproduct is a biochemical, expression includes the creation of thatbiochemical and any precursors. Expression of a gene produces a “geneproduct.” As used herein, a gene product can be either a nucleic acid,e.g., a messenger RNA produced by transcription of a gene, or apolypeptide that is translated from a transcript. Gene productsdescribed herein further include nucleic acids with post transcriptionalmodifications, e.g., polyadenylation, or polypeptides with posttranslational modifications, e.g., methylation, glycosylation, theaddition of lipids, association with other protein subunits, proteolyticcleavage, and the like.

Terms such as “treating” or “treatment” or “to treat” or “alleviating”or “to alleviate” refer to therapeutic measures that cure, slow down,lessen symptoms of, and/or halt or slow the progression of an existingdiagnosed pathologic condition or disorder. Terms such as “prevent,”“prevention,” “avoid,” “deterrence” and the like refer to prophylacticor preventative measures that prevent the development of an undiagnosedtargeted pathologic condition or disorder. Thus, “those in need oftreatment” can include those already with the disorder; those prone tohave the disorder; and those in whom the disorder is to be prevented.

By “subject” or “individual” or “animal” or “patient” or “mammal,” ismeant any subject, particularly a mammalian subject, for whom diagnosis,prognosis, or therapy is desired. Mammalian subjects include humans,domestic animals, farm animals, and zoo, sports, or pet animals such asdogs, cats, guinea pigs, rabbits, rats, mice, horses, swine, cows,bears, and so on.

As used herein, phrases such as “a subject that would benefit fromtherapy” and “an animal in need of treatment” includes subjects, such asmammalian subjects, that would benefit from administration of a bindingmolecule such as an antibody, comprising one or more antigen bindingdomains. Such binding molecules, e.g., antibodies, can be used, e.g.,for diagnostic procedures and/or for treatment or prevention of adisease.

IgM Binding Molecules

IgM is the first immunoglobulin produced by B cells in response tostimulation by antigen and is present at around 1.5 mg/ml in serum witha half-life of 5 days. IgM is typically a pentameric or hexamericmolecule. An IgM binding unit typically includes two light chains andtwo heavy chains. While IgG contains three heavy chain constant domains(CH1, CH2 and CH3), the heavy (μ) chain of IgM additionally contains afourth constant domain (CH4), that includes a C-terminal “tailpiece.”The human IgM constant region typically comprises the amino acidsequence SEQ ID NO: 1 (see Table 3). The human Cμ1 region ranges fromabout amino acid 5 to about amino acid 102 of SEQ ID NO: 1; the humanCμ2 region ranges from about amino acid 114 to about amino acid 205 ofSEQ ID NO: 1, the human Cμ3 region ranges from about amino acid 224 toabout amino acid 319 of SEQ ID NO: 1, the Cμ4 region ranges from aboutamino acid 329 to about amino acid 430 of SEQ ID NO: 1, and thetailpiece ranges from about amino acid 431 to about amino acid 453 ofSEQ ID NO: 1.

Five IgM binding units can form a complex with an additional smallpolypeptide chain (the J-chain) to form an IgM antibody. The precursorhuman J-chain comprises the amino acid sequence SEQ ID NO: 7 (Table 3).The first 22 amino acids of SEQ ID NO: 7 is the secretory signal peptideand the mature human J-chain starts at amino acid 23 of SEQ ID NO: 7.Without the J-chain, IgM binding units typically assemble into ahexamer. While not wishing to be bound by theory, the assembly of IgMbinding units into a hexameric or pentameric binding molecule is thoughtto involve the Cμ3, Cμ4 and tailpiece domains. Accordingly, a hexamericor pentameric binding molecule provided in this disclosure typicallyincludes IgM constant regions that include at least the Cμ3, Cμ4, andtailpiece domains.

An IgM heavy chain constant region can additionally include a Cμ2 domainor a fragment thereof, a Cμ1 domain or a fragment thereof, and/or otherIgM heavy chain domains. In certain aspects, a binding molecule asprovided herein can include a complete IgM heavy (μ) chain constantregion (e.g., SEQ ID NO: 1), or a variant, derivative, or analogthereof.

The Complement System and Complement-Dependent Cytotoxicity

The complement system comprises more than 30 glycoproteins, from which20 are present in plasma and 10 are cell-associated regulators orreceptors. Activation of the complement cascade induces diverse immuneeffector functions including cell lysis, phagocytosis, chemotaxis andimmune cell activation. Complement can be activated by 3 differentpathways: the classical, the alternative and the mannose-binding lectinpathway which all converge on the level of C3 protein and lead tocomplement-dependent cytotoxicity of the target cell by the formation ofthe membrane-attack complex (MAC). IgM and certain subclasses of IgGantibodies in immune complexes activate the classical complementpathway. The formation of an antigen-antibody complex inducesconformational changes in the Fc portion of the IgM or IgG molecule thatexpose a binding site for the C1 component of the complement system. C1in serum is a macromolecular complex consisting of C1q and two moleculeseach of C1r and C1s. Binding of C1q to Fc-binding sites induces aconformational change in C1r and C1s. Subsequently, proteolyticallyactivated C1r cleaves C1s resulting in C1s activation. C1s then cleavesC2 and C4 to generate C2a, C2b, C4a, and C4b. C2a and C4b together formthe C3 convertase. The cleavage of the central component C3 by the C3convertase leads to formation of C3b, some of which binds to the plasmamembrane of the target cell. Membrane-bound C3b interacts with the C3convertase, leading to the formation of the C5 convertase. Consequently,C5 is cleaved into C5a and C5b. The activation of the terminal pathwayleads to the deposition of the components C5b-C9 into the opsonizedtarget cell membrane forming the membrane-attack complex, eventuallycausing complement dependent cytotoxicity (CDC).

The end result of complement dependent cytolysis is the formation of apore in the lipid bilayer membrane of a cell that destroys membraneintegrity. Complement-dependent cytotoxicity assays (CDC assays) testthe efficacy of antibodies to activate the complement immune pathway toinitiate a membrane-attack complex and lysis of targeted cells. Onemethod for a CDC assay is to mix target cells bound by the antibodybeing evaluated with an additive, e.g., serum, that contains thecomponents of the complement system and then measure cell death. Celldeath can be measured, e.g., by pre-loading the target cells with aradioactive compound, which upon death is released from the cells, andthe efficacy of the antibody to mediate cell death is measured byradioactivity level. Non-radioactive CDC assays, e.g., theCELLTITER-GLO® assay available from Promega, measure the release ofabundant cell components, like ATP, with fluorescent or luminescentmeasurements. In the event of CDC, the mixture results in cell lysis andgeneration of a luminescent signal proportional to the amount of ATPpresent. The amount of ATP is directly proportional to the number ofcells present in culture.

Modified Human IgM Constant Regions with Reduced CDC Activity

This disclosure provides a modified human IgM constant region that, whenexpressed as part of a modified target-specific human IgM antibodydirected to a target antigen expressed on a cell, exhibits reduced CDCactivity of the cell in the presence of complement, relative to acorresponding wild-type human IgM antibody. By “corresponding wild-typehuman IgM antibody” is meant a wild-type IgM antibody that is identicalto the antibody comprising the modified human IgM constant region exceptfor the modification or modifications in the constant region affectingCDC activity. For example, the “corresponding wild-type human IgMantibody” will comprise identical VH and VL regions and any othermodifications or truncations that that the modified human IgM antibodymight have other than the modifications affecting CDC activity. Incertain aspects, the modified human IgM constant region comprises one ormore amino acid substitutions, e.g., in or close to the Cμ3 domain,e.g., in the region extending from about amino acid T302 of SEQ ID NO: 1to about amino acid K322 of SEQ ID NO: 1, e.g., at least one, at leasttwo, or at least three or more amino acid substitutions at positionT302, C303, T304, V305, T306, H307, T308, D309, L310, P311, S312, P313,L314, K315, Q316, T317, I318, S319, R320, P321, and/or K322 of SEQ IDNO: 1 relative to a wild-type human IgM constant region. While notwishing to be bound by theory, the C1q component of complement isthought to associate with the human IgM constant region at least throughcertain amino acid residues present in the Cμ3 domain. Assays formeasuring CDC are well known to those of ordinary skill in the art, andexemplary assays are described herein.

In certain aspects, a modified human IgM constant region as providedherein comprises a substitution relative to a wild-type human IgMconstant region at position P311 of SEQ ID NO: 1. In other aspects amodified IgM constant region as provided herein comprises a substitutionrelative to a wild-type human IgM constant region at position P313 ofSEQ ID NO: 1. In other aspects a modified IgM constant region asprovided herein comprises a substitution relative to a wild-type humanIgM constant region at position L310 of SEQ ID NO: 1. In other aspects amodified IgM constant region as provided herein comprises a substitutionrelative to a wild-type human IgM constant region at position K315 ofSEQ ID NO: 1. In other aspects a modified IgM constant region asprovided herein contains a combination of substitutions relative to awild-type human IgM constant region at two or more of positions L310 ofSEQ ID NO: 1, P311 of SEQ ID NO: 1, P313 of SEQ ID NO: 1, and/or K315 ofSEQ ID NO: 1. A modified IgM constant region as provided herein can besubstituted at amino acid position P311 of SEQ ID NO: 1 with, e.g.,alanine (P311A) (SEQ ID NO: 2), serine (P311S), or glycine (P311G). Amodified IgM constant region as provided herein can be substituted atamino acid position P313 of SEQ ID NO: 1 with, e.g., alanine (P313A),serine (P313S) (SEQ ID NO: 3), or glycine (P313G). A modified IgMconstant region as provided herein can be substituted at amino acidposition L310 of SEQ ID NO: 1 with, e.g., alanine (L310A) (SEQ ID NO:15), serine (L310S), glycine (L310G), or aspartic acid (L310D) (SEQ IDNO: 23). A modified IgM constant region as provided herein can besubstituted at amino acid position K315 of SEQ ID NO: 1 with, e.g.,alanine (K315A) (SEQ ID NO: 16), serine (K315S), glycine (K315G),aspartic acid (K315D) (SEQ ID NO: 24), or glutamine (K315Q) (SEQ ID NO:25). A modified IgM constant region as provided herein can besubstituted at amino acid positions P311 and P313 of SEQ ID NO: 1 with,e.g., alanine (P311A) and serine (P313S), respectively (SEQ ID NO: 4),or any combination of alanine, serine, and/or glycine. A modified IgMconstant region as provided herein can be substituted at amino acidpositions L310 and K315 of SEQ ID NO: 1 with, e.g., alanine (L310A,K315A) (SEQ ID NO: 17), or serine (L310S, K315S) (SEQ ID NO: 18), or anycombination of alanine, serine, aspartic acid, glutamine, and/orglycine. A modified IgM constant region as provided herein can besubstituted at amino acid positions L310 and P311 of SEQ ID NO: 1 with,e.g., alanine (L310A, P311A) (SEQ ID NO: 19), or any combination ofalanine, serine, aspartic acid, glutamine, and/or glycine. A modifiedIgM constant region as provided herein can be substituted at amino acidpositions L310 and P313 of SEQ ID NO: 1 with, e.g., alanine and serine,respectively (L310A, P313S) (SEQ ID NO: 20), or any combination ofalanine, serine, aspartic acid, glutamine, and/or glycine. A modifiedIgM constant region as provided herein can be substituted at amino acidpositions P311 and K315 of SEQ ID NO: 1 with, e.g., alanine (P311A,K315A) (SEQ ID NO: 21), or any combination of alanine, serine, asparticacid, glutamine, and/or glycine. A modified IgM constant region asprovided herein can be substituted at amino acid positions P313 and K315of SEQ ID NO: 1 with, e.g., serine and alanine, respectively (P313S,K315A) (SEQ ID NO: 22), or any combination of alanine, serine, asparticacid, glutamine, and/or glycine.

In certain aspects, the complement-dependent cytotoxicity activity (CDC)of a target-specific IgM antibody comprising a modified human IgMconstant region as provided herein comprising, e.g., an amino acidsubstitution at L310, P311, P313, and/or K315, e.g., L310A, L310S,L310G, L310D, P311A, P311S, P311G, P313A, P313S, P313G, K315A, K315S,K315G, K315D, and/or K315Q, or any combination thereof, can be reducedby at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or100% relative to a corresponding wild-type IgM antibody, i.e., awild-type target-specific IgM antibody that is identical except for themodified human IgM constant region.

In certain aspects, the antibody concentration effecting 50% CDCactivity (EC₅₀) of a target-specific IgM antibody comprising a modifiedhuman IgM constant region as provided herein comprising, e.g., an aminoacid substitution at L310, P311, P313, and/or K315, e.g., L310A, L310S,L310G, L310D, P311A, P311S, P311G, P313A, P313S, P313G, K315A, K315S,K315G, K315D, and/or K315Q, or any combination thereof, can be increasedby at least 2-fold, at least 5-fold, at least 10-fold, at least 20-fold,and least 30-fold, at least 40-fold, at least 50-fold, at least 60-fold,at least 70-fold, at least 80-fold, at least 90-fold, or at least100-fold relative to a corresponding wild-type IgM antibody, i.e., awild-type target-specific IgM antibody that is identical except for themodified human IgM constant region.

Modified human IgM constant regions as provided herein can beconstructed by standard mutagenesis methods well known to those ofordinary skill in the art or can be obtained from a variety ofcommercial vendors. Methods for mutagenesis and nucleotide sequencealterations are well known in the art. See, for example, Walker andGaastra, eds. (1983) Techniques in Molecular Biology (MacMillanPublishing Company, New York); Kunkel, Proc. Natl. Acad. Sci. USA82:488-492 (1985); Kunkel et al., Methods Enzymol. 154:367-382 (1987);Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (ColdSpring Harbor, N.Y.); U.S. Pat. No. 4,873,192; and the references citedtherein; herein incorporated by reference. Guidance as to appropriateamino acid substitutions that do not affect biological activity of thepolypeptide of interest can be found in the model of Dayhoff et al.(1978) in Atlas of Protein Sequence and Structure (Natl. Biomed. Res.Found., Washington, D.C.), pp. 345-352, herein incorporated by referencein its entirety. The model of Dayhoff et al. uses the Point AcceptedMutation (PAM) amino acid similarity matrix (PAM 250 matrix) todetermine suitable conservative amino acid substitutions. In certainaspects, conservative substitutions, such as exchanging one amino acidwith another having similar properties are used. Examples ofconservative amino acid substitutions as taught by the PAM 250 matrix ofthe Dayhoff et al. model include, but are not limited to, Gly↔Ala,Val↔Ile↔Leu, Asp↔Glu, Lys↔Arg, Asn↔Gln, and Phe↔Trp↔Tyr.

Pentameric or Hexameric Modified Human IgM Antibodies

In another aspect, this disclosure provides a modified human IgMantibody comprising a modified human IgM constant region as providedherein, and further comprising a heavy chain variable region (VH)situated amino terminal to the modified human IgM constant region thatspecifically binds to a target antigen (alone or in combination withlight chain variable region (VL)) and exhibits decreasedcomplement-dependent cytotoxicity (CDC) of cells expressing the targetantigen and/or an increased antibody concentration effecting 50% CDCactivity (EC₅₀) relative to a corresponding wild-type human IgMantibody, i.e., a wild-type target-specific IgM antibody that isidentical except for the modified human IgM constant region. In certainaspects, the modified human IgM antibody comprises one or more aminoacid substitutions, e.g., in or close to the Cμ3 domain, e.g., in theregion extending from about amino acid T302 of SEQ ID NO: 1 to aboutamino acid K322 of SEQ ID NO: 1, e.g., at least one, at least two, or atleast three or more amino acid substitutions at position T302, C303,T304, V305, T306, H307, T308, D309, L310, P311, S312, P313, L314, K315,Q316, T317, I318, S319, R320, P321, and/or K322 of SEQ ID NO: 1 relativeto a wild-type human IgM constant region. While not wishing to be boundby theory, the C1q component of complement is thought to associate withthe human IgM constant region at least through certain amino acidresidues present in the Cμ3 domain. Assays for measuring CDC are wellknown to those of ordinary skill in the art, and exemplary assays aredescribed herein.

In certain aspects, a modified human IgM antibody as provided hereincomprises a substitution relative to a wild-type human IgM antibody atposition P311 of SEQ ID NO: 1. In other aspects, a modified human IgMantibody as provided herein contains a substitution relative to awild-type human IgM antibody at position P313 of SEQ ID NO: 1. In otheraspects a modified human IgM antibody as provided herein contains asubstitution relative to a wild-type human IgM antibody at position L310of SEQ ID NO: 1. In other aspects a modified human IgM antibody asprovided herein contains a substitution relative to a wild-type humanIgM antibody at position K315 of SEQ ID NO: 1. In other aspects amodified IgM antibody as provided herein contains a combination ofsubstitutions relative to a wild-type human IgM antibody at two or moreof positions L310 of SEQ ID NO: 1, P311 of SEQ ID NO: 1, P313 of SEQ IDNO: 1, and/or K315 of SEQ ID NO: 1. A modified IgM antibody as providedherein can be substituted at amino acid position P311 of SEQ ID NO: 1with, e.g., alanine (P311A) (SEQ ID NO: 2), serine (P311S), or glycine(P311G). A modified IgM antibody as provided herein can be substitutedat amino acid position P313 of SEQ ID NO: 1 with, e.g., alanine (P313A),serine (P313S) (SEQ ID NO: 3), or glycine (P313G). A modified IgMantibody as provided herein can be substituted at amino acid positionL310 of SEQ ID NO: 1 with, e.g., alanine (L310A) (SEQ ID NO: 15), serine(L310S), glycine (L310G) or aspartic acid (L310D) (SEQ ID NO: 23). Amodified IgM antibody as provided herein can be substituted at aminoacid position K315 of SEQ ID NO: 1 with, e.g., alanine (K315A) (SEQ IDNO: 16), serine (K315S), glycine (K315G), aspartic acid (K315D) (SEQ IDNO: 24), or glutamine (K315Q) (SEQ ID NO: 25). A modified IgM antibodyas provided herein can be substituted at amino acid positions P311 andP313 of SEQ ID NO: 1 with, e.g., alanine (P311A) and serine (P313S),respectively (SEQ ID NO: 4), or any combination of alanine, serine,and/or glycine. A modified IgM antibody as provided herein can besubstituted at amino acid positions L310 and K315 of SEQ ID NO: 1 with,e.g., alanine (L310A, K315A) (SEQ ID NO: 17), or serine (L310S, K315S)(SEQ ID NO: 18), or any combination of alanine, serine, aspartic acid,glutamine, and/or glycine. A modified IgM antibody as provided hereincan be substituted at amino acid positions L310 and P311 of SEQ ID NO: 1with, e.g., alanine (L310A, P311A) (SEQ ID NO: 19), or any combinationof alanine, serine, aspartic acid, glutamine, and/or glycine. A modifiedIgM antibody as provided herein can be substituted at amino acidpositions L310 and P313 of SEQ ID NO: 1 with, e.g., alanine and serine,respectively (L310A, P313S) (SEQ ID NO: 20), or any combination ofalanine, serine, aspartic acid, glutamine, and/or glycine. A modifiedIgM antibody as provided herein can be substituted at amino acidpositions P311 and K315 of SEQ ID NO: 1 with, e.g., alanine (P311A,K315A) (SEQ ID NO: 21), or any combination of alanine, serine, asparticacid, glutamine, and/or glycine. A modified IgM antibody as providedherein can be substituted at amino acid positions P313 and K315 of SEQID NO: 1 with, e.g., serine and alanine, respectively (P313S, K315A)(SEQ ID NO: 22), or any combination of alanine, serine, aspartic acid,glutamine, and/or glycine.

In certain aspects, the complement-dependent cytotoxicity activity (CDC)of the modified IgM antibody as provided herein comprising, e.g., anamino acid substitution at L310, P311, P313, and/or K315, e.g., L310A,L310S, L310G, L310D, P311A, P311S, P311G, P313A, P313S, P313G, K315A,K315S, K315G, K315D, and/or K315Q, or any combination thereof, can bereduced by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%,95%, or 100% relative to a corresponding wild-type IgM antibody, i.e., awild-type target-specific IgM antibody that is identical except for themodified human IgM constant region.

In certain aspects, antibody concentration effecting 50% CDC activity(EC₅₀) of the IgM antibody as provided herein, comprising, e.g., anamino acid substitution at L310, P311, P313, and/or K315, e.g., L310A,L310S, L310G, L310D, P311A, P311S, P311G, P313A, P313S, P313G, K315A,K315S, K315G, K315D, and/or K315Q, or any combination thereof, can beincreased by at least 2-fold, at least 5-fold, at least 10-fold, atleast 20-fold, and least 30-fold, at least 40-fold, at least 50-fold, atleast 60-fold, at least 70-fold, at least 80-fold, at least 90-fold, orat least 100-fold relative to a corresponding wild-type IgM antibody,i.e., a wild-type target-specific IgM antibody that is identical exceptfor the modified human IgM constant region.

A modified human IgM antibody as provided herein can be hexameric orpentameric, comprising five or six IgM “binding units” as definedherein, one or more of which can specifically bind to a target antigenof interest. The disclosure encompasses a modified human IgM antibodythat specifically binds to any target antigen. In certain aspects thetarget antigen is capable of expression on the surface of a cell, e.g.,a eukaryotic cell. Target antigens can include, without limitation,tumor antigens, other oncologic targets, immuno-oncologic targets suchas immune checkpoint inhibitors, infectious disease antigens, such asviral antigens expressed on the surface of infected cells, targetantigens involved in blood-brain-barrier transport, target antigensinvolved in neurodegenerative diseases and neuroinflammatory diseases,and any combination thereof. Non-limiting examples of target antigens,as well as non-limiting examples of antibody binding domains that bindto such target antigens can be found, e.g., in PCT Publication Nos. WO2016/141303, WO 2016/168758, WO 2016/154593, WO 2016/118641, WO2015/153912, WO 2015/053887, WO 2013/120012, WO/2017/059387,WO/2017/059380, WO/2018/017888, WO/2018/017889, WO/2018/017761, andWO/2018/017763, the disclosures of which are incorporated herein byreference in their entireties.

In certain aspects, the disclosure provides a pentameric or hexamericmodified human IgM antibody comprising five or six bivalent bindingunits, respectively, where each binding unit includes two modified humanIgM heavy chain constant regions or fragments thereof as providedherein.

Where the modified human IgM antibody provided herein is pentameric, theantibody can further comprise a J-chain, or functional fragment thereof,or variant thereof. In certain aspects, the J-chain is a modifiedJ-chain comprising a heterologous moiety or one or more heterologousmoieties, e.g., a heterologous polypeptide sequence, e.g., an extraneousbinding domain introduced into the native sequence. In certain aspectsthe extraneous binding domain specifically binds to CD3, e.g., CD3ε. Incertain aspects the modified J-chain comprises V15J (SEQ ID NO: 9) orJ15V (SEQ ID NO: 11).

An IgM heavy chain constant region can include one or more of a Cμ1domain, a Cμ2 domain, a Cμ3 domain (as provided herein, the Cμ3 cancomprise one or more amino acid substitutions), and/or a Cμ4 domain,provided that the constant region can serve a desired function in themodified human IgM antibody, e.g., associate with second IgM constantregion to form an binding unit, or associate with other binding units toform a hexamer or a pentamer. In certain aspects the two modified humanIgM heavy chain constant regions or fragments thereof within anindividual binding unit each comprise a modified Cμ3 domain (e.g., withsubstitutions at one or more of L310 of SEQ ID NO: 1, P311 of SEQ ID NO:1, P313 of SEQ ID NO: 1, K315 of SEQ ID NO: 1, and/or a combinationthereof) or fragment thereof, a Cμ4 domain or fragment thereof, atailpiece (TP) or fragment thereof, or any combination of a modified Cμ3domain a Cμ4 domain, and a TP or fragment thereof. In certain aspectsthe two modified human IgM heavy chain constant regions or fragmentsthereof within an individual binding unit each further comprise a Cμ2domain or fragment thereof, a Cμ1 domain or fragment thereof, or a Cμ1domain or fragment thereof and a Cμ2 domain or fragment thereof.

In certain aspects each of the two modified human IgM heavy chainconstant regions in a given binding unit is associated with an antigenbinding domain, for example a heavy chain variable region (VH) or an Fvportion of an antibody, e.g., a VH and a VL of an antibody.

Modified J-Chains

In certain aspects a modified human IgM antibody as provided herein canbe bispecific, incorporating a modified J-chain. As provided herein andin PCT Publication Nos. WO 2015/153912 WO/2017/059387, andWO/2017/059380, a modified J-chain can comprise a heterologous moiety,e.g., a heterologous polypeptide, e.g., an extraneous binding domain,which can include, for example, a polypeptide binding domain capable ofspecifically binding to a target. The binding domain can be, forexample, an antibody or antigen-binding fragment thereof, anantibody-drug conjugate or antigen-binding fragment thereof, or anantibody-like molecule. A polypeptide binding domain can be introducedinto a J-chain by appropriately selecting the location and type ofaddition (e.g. direct or indirect fusion, chemical tethering, etc.).

In certain aspects, the binding domain can be an antibody or anantigen-binding fragment of an antibody, including monospecific,bispecific, and multi-specific antibodies and antibody fragments. Theantibody fragment can be, without limitation, a Fab fragment, a Fab′fragment, a F(ab′)₂ fragment, an scFv, (scFv)₂ fragment, single-chainantibody molecules, minibodies, or multispecific antibodies formed fromantibody fragments. In certain aspects, the antibody fragment is a scFv.

In other aspects, the binding domain can be an antibody-like molecule,for example, a human domain antibody (dAb), Dual-Affinity Re-Targeting(DART) molecule, a diabody, a di-diabody, dual-variable domain antibody,a Stacked Variable Domain antibody, a Small Modular ImmunoPharmaceutical (SMIP), a Surrobody, a strand-exchange engineered domain(SEED)-body, or TandAb.

The binding domain can be introduced into the native J-chain sequence atany location that allows the binding of the binding domain to itsbinding target without interfering with the binding of a recipient IgMmolecule to its binding target or binding targets or the ability of theJ-chain to effectively incorporate into an IgM pentamer. In certainaspects the binding domain can be inserted at or near the C-terminus, ator near the mature N-terminus (e.g., amino acid number 23 of SEQ ID NO:7 following cleavage of the signal peptide) or at an internal locationthat, based on the three-dimensional structure of the J-chain isaccessible. In certain aspects, the binding domain can be introducedinto the native sequence J-chain without about 10 residues from theC-terminus or without about 10 amino acid residues from the matureN-terminus (amino acid 23) of the human J-chain of SEQ ID NO: 7. Inanother aspect, the binding domain can be introduced into the nativesequence human J-chain of SEQ ID NO: 7 in between cysteine residues 113and 122 of SEQ ID NO: 7, or at an equivalent location of another nativesequence J-chain. In a further aspect, the binding domain can beintroduced into a native sequence J-chain, such as a J-chain of SEQ IDNO: 7, at or near a glycosylation site. In certain aspects, the bindingdomain can be introduced into the native sequence human J-chain of SEQID NO: 7 within about 10 amino acid residues from the C-terminus.

Introduction can be accomplished by direct or indirect fusion, i.e. bythe combination of the J-chain and binding domain in one polypeptidechain by in-frame combination of their coding nucleotide sequences, withor without a peptide linker. The peptide linker (indirect fusion), ifused, can be about 1 to 50, or about 1 to 40, or about 1 to 30, or about1 to 20, or about 1 to 10, or about 10 to 20 amino acids in length, andcan be present at one or both ends of the binding domain to beintroduced into the J-chain sequence. In certain aspects, the peptidelinker is about 10 to 20, or 10 to 15 amino acids long. In certainaspects the peptide linker is 15 amino acids long. In certain aspectsthe peptide linker is (GGGGS)₃ (SEQ ID NO: 12).

It is also possible to introduce more than one heterologous polypeptide,e.g., more than one binding domain or other moiety, into a J-chain.

The modified J-chain can be produced by well-known techniques ofrecombinant DNA technology, by expressing a nucleic acid encoding themodified J-chain in a suitable prokaryotic or eukaryotic host organism.

The modified J-chain can also be co-expressed with the heavy and lightchains of a recipient modified human IgM antibody as described elsewhereherein. The recipient antibody, prior to modified J-chain incorporation,can be monospecific, bispecific or multi-specific, e.g., a monospecific,bispecific, or multispecific modified human IgM antibody. Bispecific andmulti-specific IgM antibodies, including antibodies, are described, forexample, in PCT Publication Nos. WO 2015/053887, and WO 2015/120474, theentire contents of which are hereby expressly incorporated by reference.

In certain aspects, a modified human IgM antibody as described hereincan include a modified J-chain with binding specificity for an immuneeffector cell, such as a T-cell, NK-cell, a macrophage, or a neutrophil.In certain aspects the effector cell is a T-cell and the binding targetis CD3 (discussed below). By activating and redirecting effector cells,e.g. effector T-cells such as cytotoxic T-cells (CTLs), to a cellexpressing a target antigen of interest, a modified human IgM antibodyas provided herein can produce an enhanced effector response against thetarget antigen, thereby further increasing potency and efficacy. Incertain aspects, the ability of a bispecific modified human IgM antibodyas provided herein to elicit T-cell mediated cytotoxicity throughbinding to CD3 via a modified J-chain is unaffected by the modificationsin the IgM constant region that reduce CDC relative to a correspondingwild-type IgM antibody.

In the case of T-cells, cluster of differentiation 3 (CD3) is amultimeric protein complex, known historically as the T3 complex, and iscomposed of four distinct polypeptide chains (ε, γ, δ, ζ) that assembleand function as three pairs of dimers (εγ, εδ, ζζ). The CD3 complexserves as a T-cell co-receptor that associates non-covalently with theT-cell receptor (TCR). Components of this CD3 complex, especially CD3ε,can be targets for a modified J-chain of a bispecific IgM or IgA bindingmolecule provided herein.

In certain aspects, a bispecific modified human IgM antibody is providedwhere the J-chain is modified to bind to CD3ε.

In certain aspects the anti-CD3ε binding domain of a modified J-chainprovided herein is a scFv. The anti CD3ε scFv can be fused at or nearthe N-terminus of the J-chain, or at or near the C-terminus of theJ-chain either directly or indirectly with a synthetic linker introducedin between the scFv and the J-chain sequences, e.g., a (GGGGS)₃ linker(SEQ ID NO: 12). In certain aspects the scFv comprises the VH and VLregions of visilizumab (Nuvion). In certain aspects the modified J-chaincomprises a scFv comprising the VH of visilizumab, a (GGGGS)₃ linker(SEQ ID NO: 12), and the VL of visilizumab.

In certain aspects the modified J-chain comprises a scFv of visilizumabfused to the N-terminus of the human J-chain through a 15-amino acid(GGGGS)₃ linker (SEQ ID NO: 12), a modified J-chain referred to hereinas V15J. V15J can further include a signal peptide to facilitatetransport and assembly into a modified human IgM antibody as providedherein. The mature V15J protein is presented as SEQ ID NO: 9, theprecursor version, comprising a 19-amino acid-immunoglobulin heavy chainsignal peptide is presented as SEQ ID NO: 8. In certain aspects themodified J-chain comprises a scFv of visilizumab fused to the C-terminusof the human J-chain through a 15-amino acid (GGGGS)₃ linker (SEQ ID NO:12), a modified J-chain referred to herein as J15V. J15V can furtherinclude a signal peptide to facilitate transport and assembly into amodified human IgM antibody as provided herein. The mature J15V proteinis presented as SEQ ID NO: 11, the precursor version, comprising the22-amino acid-human J-chain signal peptide is presented as SEQ ID NO:10. In certain aspects, other signal peptides can be used. Selection andinclusion of suitable signal peptides to facilitate expression,secretion, and incorporation of a modified J-chain into a modified humanIgM antibody as provided herein is well within the capabilities of aperson of ordinary skill in the art.

This disclosure employs, unless otherwise indicated, conventionaltechniques of cell biology, cell culture, molecular biology, transgenicbiology, microbiology, recombinant DNA, and immunology, which are withinthe skill of the art. Such techniques are explained fully in theliterature. See, for example, Sambrook et al., ed. (1989) MolecularCloning A Laboratory Manual (2nd ed.; Cold Spring Harbor LaboratoryPress); Sambrook et al., ed. (1992) Molecular Cloning: A LaboratoryManual, (Cold Springs Harbor Laboratory, NY); D. N. Glover ed., (1985)DNA Cloning, Volumes I and II; Gait, ed. (1984) OligonucleotideSynthesis; Mullis et al. U.S. Pat. No. 4,683,195; Hames and Higgins,eds. (1984) Nucleic Acid Hybridization; Hames and Higgins, eds. (1984)Transcription And Translation; Freshney (1987) Culture Of Animal Cells(Alan R. Liss, Inc.); Immobilized Cells And Enzymes (IRL Press) (1986);Perbal (1984) A Practical Guide To Molecular Cloning; the treatise,Methods In Enzymology (Academic Press, Inc., N.Y.); Miller and Caloseds. (1987) Gene Transfer Vectors For Mammalian Cells, (Cold SpringHarbor Laboratory); Wu et al., eds., Methods In Enzymology, Vols. 154and 155; Mayer and Walker, eds. (1987) Immunochemical Methods In CellAnd Molecular Biology (Academic Press, London); Weir and Blackwell,eds., (1986) Handbook Of Experimental Immunology, Volumes I-IV;Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, ColdSpring Harbor, N.Y., (1986); and in Ausubel et al. (1989) CurrentProtocols in Molecular Biology (John Wiley and Sons, Baltimore, Md.).

General principles of antibody engineering are set forth in Borrebaeck,ed. (1995) Antibody Engineering (2nd ed.; Oxford Univ. Press). Generalprinciples of protein engineering are set forth in Rickwood et al., eds.(1995) Protein Engineering, A Practical Approach (IRL Press at OxfordUniv. Press, Oxford, Eng.). General principles of antibodies andantibody-hapten binding are set forth in: Nisonoff (1984) MolecularImmunology (2nd ed.; Sinauer Associates, Sunderland, Mass.); and Steward(1984) Antibodies, Their Structure and Function (Chapman and Hall, NewYork, N.Y.). Additionally, standard methods in immunology known in theart and not specifically described can be followed as in CurrentProtocols in Immunology, John Wiley & Sons, New York; Stites et al.,eds. (1994) Basic and Clinical Immunology (8th ed; Appleton & Lange,Norwalk, Conn.) and Mishell and Shiigi (eds) (1980) Selected Methods inCellular Immunology (W.H. Freeman and Co., NY).

Standard reference works setting forth general principles of immunologyinclude Current Protocols in Immunology, John Wiley & Sons, New York;Klein (1982) J., Immunology: The Science of Self-Nonself Discrimination(John Wiley & Sons, NY); Kennett et al., eds. (1980) MonoclonalAntibodies, Hybridoma: A New Dimension in Biological Analyses (PlenumPress, NY); Campbell (1984) “Monoclonal Antibody Technology” inLaboratory Techniques in Biochemistry and Molecular Biology, ed. Burdenet al., (Elsevier, Amsterdam); Goldsby et al., eds. (2000) KubyImmunology (4th ed.; W.H. Freeman and Co., NY); Roitt et al. (2001)Immunology (6th ed.; London: Mosby); Abbas et al. (2005) Cellular andMolecular Immunology (5th ed.; Elsevier Health Sciences Division);Kontermann and Dubel (2001) Antibody Engineering (Springer Verlag);Sambrook and Russell (2001) Molecular Cloning: A Laboratory Manual (ColdSpring Harbor Press); Lewin (2003) Genes VIII (Prentice Hall, 2003);Harlow and Lane (1988) Antibodies: A Laboratory Manual (Cold SpringHarbor Press); Dieffenbach and Dveksler (2003) PCR Primer (Cold SpringHarbor Press).

All the references cited above, as well as all references cited herein,are incorporated herein by reference in their entireties.

The following examples are offered by way of illustration and not by wayof limitation.

EXAMPLES Example 1: Effects of Cμ3 Domain Mutations on IgM Assembly

Plasmid variants of pFUSEss-CHIg-hM*03-encoding modified human IgMconstant regions with single site mutations in the Cμ3 domain, P311A(SEQ ID NO: 2), P313S (SEQ ID NO: 3), both P311A and P313S (SEQ ID NO:4), D294G (SEQ ID NO: 5), and S283N (SEQ ID NO: 6), were designed andsubmitted to a commercial vendor for synthesis. Exemplary plasmidconstructs that can express wild-type or modified human pentameric orhexameric IgM antibodies comprising the wild-type or modified IgMconstant regions, and that can specifically bind to CD20, were producedby the following method.

DNA fragments encoding the VH and VL regions of 1.5.3 (SEQ ID NOs 13 and14, respectively) were synthesized by a commercial vendor (Genescript),with an EcoRV restriction site on the ‘5 end and an XbaI restrictionsite on the 3’ end for subcloning into heavy chain and light chainexpression vectors. The synthesized DNA constructs were re-suspended inTris-EDTA buffer at 1 μg/ml. DNA samples (1 μg) were digested with EcoRVand XbaI, and the synthesized VH and VL were separated from the carrierplasmid DNA by electrophoresis. The digested DNA was ligated topre-digested plasmid DNA (pFUSEss-CHIg-hM*03 available from Invivogen orthe modified constructs described above for μ chain, pFUSE2ss-CLIg-hkfor kappa chain, available from Invivogen) by standard molecular biologytechniques. The ligated DNAs were transformed into competent bacteriaand plated on LB plates with multiple selective antibiotics. Severalbacterial colonies were picked, and DNA preparations were made bystandard molecular biology techniques. The constructs encoding the heavychain and light chains were verified by sequencing.

The plasmid constructs encoding the IgM heavy chains and light chains,or the heavy chains, light chains, and J-chain were cotransfected intoCHO cells, and cells that express wild-type or modified CD20 IgMantibodies, either with or without J-chain, were selected, all accordingto standard methods.

Antibodies present in the cell supernatants were recovered using CaptureSelect IgM (Catalog 2890.05, BAC, Thermo Fisher) according to themanufacturer's protocol. Antibodies were evaluated on SDS PAGE undernon-reducing conditions to show assembly as previously described, e.g.,in PCT Publication No. WO 2016/141303 (FIG. 1 and FIG. 5), or underreducing conditions for certain bispecific antibodies (FIG. 5).

Control antibodies (IgM (pure), IgM+J (pure) (an IgM antibody withwild-type J chain) and IgM (an IgM lacking a J chain)) and the IgM Cμ3domain mutants, S283N, P313S, P311A, and D294G, were evaluated on SDSPAGE under non-reducing conditions to show assembly of the antibodies.NuPage LDS Sample Buffer (Life Technologies) was added to samples beforeloading onto a NativePage Novex 3-12% bis-Tris Gel (Life TechnologiesCatalog #BN1003). Novex Tris-Acetate SDS Running Buffer (LifeTechnologies Catalog #LA0041) was used for gel electrophoresis. The gelwas run until the dye front reached the bottom of the gel. Afterelectrophoresis, the gel was stained with Colloidal Blue Stain (LifeTechnologies Catalog #LC6025).

The results, shown in FIG. 1, demonstrate that the IgM Cμ3 domain mutantantibodies assemble as well as control antibodies.

Control bispecific antibody (1.5.3 IgM V15J) and the 1.5.3 IgM V15J Cμ3domain mutants, P313S, P311A, and the P311A/P313S double mutant, wereevaluated on SDS PAGE under non-reducing (“hybrid”) and reducingconditions to show assembly of the antibodies. NuPage LDS Sample Buffer(Life Technologies) was added to samples before loading onto aNativePage Novex 3-12% bis-Tris Gel (Life Technologies Catalog #BN1003).Novex Tris-Acetate SDS Running Buffer (Life Technologies Catalog#LA0041) was used for gel electrophoresis. The gel was run until the dyefront reached the bottom of the gel. After electrophoresis, the gel wasstained with Colloidal Blue Stain (Life Technologies Catalog #LC6025).

The results, shown in FIG. 5, demonstrate that the bispecific IgM Cμ3domain mutant antibodies assemble as well as control antibody.

Example 2: Complement Dependent Cytotoxicity Activity of IgM Cμ3 Mutants

The CD20-expressing Ramos (ATCC cat. #CRL-1596), cell line was obtainedfrom ATCC and DSMZ. 50,000 cells were seeded in a 96-well plate. Cellswere treated with the wild-type control antibodies, 1.5.3 IgM, 1.5.3 IgGand 1.5.3 IgM×V15J, as well as the IgM Cμ3 domain single mutants (P311A,P313S, D294G, and S283N). Human serum complement (Quidel cat. #A113) wasadded to antibody-treated cells at a final concentration of 10%. Thereaction mixtures were incubated at 37° C. for 4 hours. CELLTITER-GLO®reagent (Promega cat. #G7572) was added at a volume equal to the volumeof culture medium present in each well. The plate was shaken for 2minutes, incubated for 10 minutes at room temperature, and luminescencewas measured on a luminometer.

The results are shown in FIG. 2. Two IgM Cμ3 single mutants, P311A andP313S, exhibited approximately 50% less cell killing than the control1.5.3 IgM antibodies in the presence of complement. IgM Cμ3 mutants,S283N and D294G, showed similar cell killing with complement to thecontrol wild-type IgMs. In the absence of complement, minimal cellkilling was observed for the 1.5.3 IgG and 1.5.3 IgM×V15J antibodies.

Example 3: Complement Dependent Cytotoxicity of BispecificAnti-CD20×Anti-CD3 IgM Cμ3 Mutants

The CD20-expressing Ramos (ATCC cat. #CRL-1596), cell line was obtainedfrom ATCC and DSMZ. 50,000 cells were seeded in a 96-well plate. Cellswere treated with control antibody, 1.5.3 IgM×V15J, and the bispecificIgM Cμ3 domain mutants (P311A×V15J, P313S×V15J, D294G×V15J, andS283N×V15J). All the antibodies included a J chain bispecific for CD20and CD3 generated and expressed as previously described, see, PCTPublication No. WO 2016/141303. Human serum complement (Quidel cat.#A113) was added to the antibody-treated cells at a final concentrationof 10%. The reaction mixtures were incubated at 37° C. for 4 hours.CELLTITER-GLO® reagent (Promega cat. #G7572) was added at a volume equalto the volume of culture medium present in each well. The plate wasshaken for 2 minutes, incubated for 10 minutes at room temperature, andluminescence was measured on a luminometer.

The results are shown in FIG. 3 and in FIG. 6. The bispecific IgM Cμ3mutants, P311A and P313S, exhibited half maximal Ramos cell killing withcomplement, whereas control 1.5.3 IgM×V15J and the bispecific IgM Cμ3mutants D294G and S283N achieved nearly maximal complement dependentcytotoxicity (90-100% effective) in the presence of complement. In theassay shown in FIG. 6, bispecific IgM Cμ3 mutant P311A exhibited maximumkilling of about 46% with complement (EC₅₀ was undefined), while theP313S mutant showed maximum killing of 31% with complement (EC₅₀ was 243μM). Complement-mediated killing was essentially eliminated in thedouble mutant, P311A/P313S (FIG. 6, see also Table 2).

Example 4: T-Cell Activation Potential of Bispecific Anti-CD20×Anti-CD3IgM Cμ3 Mutants

Engineered Jurkat T-cells (Promega CS176403) and RPMI8226 cells (ATCCCCL-155) were cultured in RPMI (Invitrogen) supplemented with 10% FetalBovine Serum (Invitrogen). Serial dilutions of bispecific 1.5.3 IgM×V15Jantibody and the bispecific IgM Cμ3 mutants, D294G×V15J, S283N×V15J,P313S×V15J, P311A×V15J, P311A/P313S×V15J, and 1.5.3 IgM (withoutJ-chain) were incubated with 7500 RPMI8226 cells in 20 μL in a white 384well assay plate for 2 h at 37° C. with 5% CO₂. The engineered Jurkatcells (25000) were added to mixture to final volume of 40 μL. Themixture was incubated for 5 h at 37° C. with 5% CO₂. The cell mixtureswere then mixed with 20 μL lysis buffer containing luciferin (Promega,CELLTITER-GLO®) to measure luciferase reporter activity. Light outputwas measured by EnVision plate reader. EC₅₀ was determined by 4parameter curve fit using Prism software.

The results are shown in FIG. 4 and in FIG. 7. All of the bispecific IgMCμ3 mutants activated T cells as effectively as the bispecific controlantibody (1.5.3 IgM×V15J). No T cell activation was observed in the IgMcontrol lacking the bispecific J chain (1.5.3 IgM).

Example 5: Complement Dependent Cytotoxicity of Additional BispecificAnti-CD20×Anti-CD3 IgM Cμ3 Mutants

To further evaluate the effect of Cμ3 mutations on CDC activity,systematic single amino acid ala substitutions were made at eachposition from T302 of SEQ ID NO: 1 to K322 of SEQ ID NO: 1. Each ofthese mutant IgM constant regions were assembled as 1.5.3 IgM V15J Cμ3domain mutants as described in Example 1, and were tested for CDCactivity as described in Example 3 and for T cell activation asdescribed in Example 4. In addition to the previously evaluatedmutations at P311 and P313, 1.5.3 IgM V15J Cμ3 domain ala substitutionsat L310 (SEQ ID NO: 15) and K315 (SEQ ID NO: 16) modestly reduced CDCactivity with an increased EC₅₀, as shown in FIG. 8 and Table 2, withoutsignificantly affecting T cell activation (data not shown).

Various combinations of double substitutions at two of positions L310,P311, P313, and K315 were also constructed as described in Example 1 andwere tested for CDC activity as described in Example 3. These includeddouble mutants L310A, K315A (SEQ ID NO: 17), L310S, K315S (SEQ ID NO:18), L310A, P311A (SEQ ID NO: 19), L310A, P313S (SEQ ID NO: 20), P311A,K315A (SEQ ID NO: 21), and P313S, K315A (SEQ ID NO: 22). The CDCactivity of these double mutants relative to wild-type human IgM issummarized in Table 2. The L310A, K315A double mutant shown an enhancedreduction in CDC activity relative to either of the single mutations.

Additional amino acid substitutions at positions L310 and K315 wereevaluated to determine the effect of charged or polar amino acids on CDCactivity. L310 was substituted with the negatively-charged aspartic acid(D, SEQ ID NO: 23), and K315 was substituted with aspartic acid (D, SEQID NO: 24) or the polar amino acid glutamine (Q, SEQ ID NO: 25). Thesemutants were tested for CDC activity as described in Example 3. Theresults are shown in FIG. 9A and FIG. 9B, and in Table 2. Theintroduction of negatively-charged amino acids at positions 310 or 315disrupted CDC activity more than the neutral ala substitutions.

TABLE 2 CDC Activity of Human IgM Cμ3 Mutants Amino Acid Residue inHuman IgM Heavy Chain % CDC SEQ Constant Region (SEQ ID Fold Relative IDNO: 1) EC₅₀ to Wild Substitution(s) NO: 309 310 311 312 313 314 315 316Increase Type WT 26 D L P S P L K Q 1 100%  L310A 27 A 2 95% P311A 28 A11 46% P313S 29 S 6 83% K315A 30 A 5 95% L310D 31 D ND 12% K315D 32 D 750% K315Q 33 Q 3 85% L310A K315A 34 A A 80 52% L310S K315S 35 S S 8 86%L310A P311A 36 A A ND 18% L310A P313S 37 A S 6 39% P311A K315A 38 A A100 29% P313S K315A 39 S A 16 47% P311A P313S 40 A S ND 25%

TABLE 3 Sequences SEQ ID NO Short Name Sequence  1 human IgMGSASAPTLFPLVSCENSPSDTSSVAVGCLAQDFLPDSITFS constantWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVM region AAQGTDEHVVCKVQHPNGNKEKNVPLPVIAELPPKVSVFVPPRDGFFGNPRKSKLICQATGFSPRQIQVSWLREGKQVGSGVTTDQVQAEAKESGPTTYKVTSTLTIKESDWLSQSMFTCRVDHRGLTFQQNASSMCVPDQDTAIRVFAIPPSFASIFLTKSTKLTCLVTDLTTYDSVTISWTRQNGEAVKTHTNISESHPNATFSAVGEASICEDDWNSGERFTCTVTHTDLPSPLKQTISRPKGVALHRPDVYLLPPAREQLNLRESATITCLVTGFSPADVFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEEWNTGETYTCVVAHEALPNRVTERTVDKSTGKP TLYNVSLVMSDTAGTCY  2 ModifiedGSASAPTLFPLVSCENSPSDTSSVAVGCLAQDFLPDSITFS human IgMWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVM constantQGTDEHVVCKVQHPNGNKEKNVPLPVIAELPPKVSVFVP regionPRDGFFGNPRKSKLICQATGFSPRQIQVSWLREGKQVGSG P311AVTTDQVQAEAKESGPTTYKVTSTLTIKESDWLSQSMFTCRVDHRGLTFQQNASSMCVPDQDTAIRVFAIPPSFASIFLTKSTKLTCLVTDLTTYDSVTISWTRQNGEAVKTHTNISESHPNATFSAVGEASICEDDWNSGERFTCTVTHTDLASPLKQTISRPKGVALHRPDVYLLPPAREQLNLRESATITCLVTGFSPADVFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEEWNTGETYTCVVAHEALPNRVTERTVDKSTG KPTLYNVSLVMSDTAGTCY  3 ModifiedGSASAPTLFPLVSCENSPSDTSSVAVGCLAQDFLPDSITFS human IgMWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVM constantQGTDEHVVCKVQHPNGNKEKNVPLPVIAELPPKVSVFVP regionPRDGFFGNPRKSKLICQATGFSPRQIQVSWLREGKQVGSG P313SVTTDQVQAEAKESGPTTYKVTSTLTIKESDWLSQSMFTCRVDHRGLTFQQNASSMCVPDQDTAIRVFAIPPSFASIFLTKSTKLTCLVTDLTTYDSVTISWTRQNGEAVKTHTNISESHPNATFSAVGEASICEDDWNSGERFTCTVTHTDLPSSLKQTISRPKGVALHRPDVYLLPPAREQLNLRESATITCLVTGFSPADVFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEEWNTGETYTCVVAHEALPNRVTERTVDKSTGKP TLYNVSLVMSDTAGTCY  4 ModifiedGSASAPTLFPLVSCENSPSDTSSVAVGCLAQDFLPDSITFS human IgMWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVM constantQGTDEHVVCKVQHPNGNKEKNVPLPVIAELPPKVSVFVP regionPRDGFFGNPRKSKLICQATGFSPRQIQVSWLREGKQVGSG P311A/P31S3VTTDQVQAEAKESGPTTYKVTSTLTIKESDWLSQSMFTCRVDHRGLTFQQNASSMCVPDQDTAIRVFAIPPSFASIFLTKSTKLTCLVTDLTTYDSVTISWTRQNGEAVKTHTNISESHPNATFSAVGEASICEDDWNSGERFTCTVTHTDLASSLKQTISRPKGVALHRPDVYLLPPAREQLNLRESATITCLVTGFSPADVFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEEWNTGETYTCVVAHEALPNRVTERTVDKSTG KPTLYNVSLVMSDTAGTCY  5 ModifiedGSASAPTLFPLVSCENSPSDTSSVAVGCLAQDFLPDSITFS human IgM WKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVM constantQGTDEHVVCKVQHPNGNKEKNVPLPVIAELPPKVSVFVP regionPRDGFFGNPRKSKLICQATGFSPRQIQVSWLREGKQVGSG D294GVTTDQVQAEAKESGPTTYKVTSTLTIKESDWLSQSMFTCRVDHRGLTFQQNASSMCVPDQDTAIRVFAIPPSFASIFLTKSTKLTCLVTDLTTYDSVTISWTRQNGEAVKTHTNISESHPNATFSAVGEASICEDGWNSGERFTCTVTHTDLPSPLKQTISRPKGVALHRPDVYLLPPAREQLNLRESATITCLVTGFSPADVFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEEWNTGETYTCVVAHEALPNRVTERTVDKSTGKP TLYNVSLVMSDTAGTCY  6 ModifiedGSASAPTLFPLVSCENSPSDTSSVAVGCLAQDFLPDSITFS human IgMWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVM constantQGTDEHVVCKVQHPNGNKEKNVPLPVIAELPPKVSVFVP regionPRDGFFGNPRKSKLICQATGFSPRQIQVSWLREGKQVGSG S283NVTTDQVQAEAKESGPTTYKVTSTLTIKESDWLSQSMFTCRVDHRGLTFQQNASSMCVPDQDTAIRVFAIPPSFASIFLTKSTKLTCLVTDLTTYDSVTISWTRQNGEAVKTHTNISESHPNATFNAVGEASICEDDWNSGERFTCTVTHTDLPSPLKQTISRPKGVALHRPDVYLLPPAREQLNLRESATITCLVTGFSPADVFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEEWNTGETYTCVVAHEALPNRVTERTVDKSTG KPTLYNVSLVMSDTAGTCY  7J-chain AA MKNHLLFWGVLAVFIKAVHVKAQEDERIVLVDNKCKCARITSRIIRSSEDPNEDIVERNIIIVPLNNRENISDPTSPLRTRFVYHLSDLCKKCDPTEVELDNQIVTATQSNICDEDSATETCYTYDRNKCYTAVVPLVYGGETKMVETALTPDACYPD  8 precursorMGWSYIILFLVATATGVHSQVQLVQSGAEVKKPGASVK modified J-VSCKASGYTFISYTMHWVRQAPGQGLEWMGYINPRSGY chainTHYNQKLKDKATLTADKSASTAYMELSSLRSEDTAVYY sequence forCARSAYYDYDGFAYWGQGTLVTVSSGGGGSGGGGSGG V15JGGSDIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQKPGKAPKRLIYDTSKLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSSNPPTFGGGTKLEIKGGGGSGGGGSGGGGSQEDERIVLVDNKCKCARITSRIIRSSEDPNEDIVERNIRIIVPLNNRENISDPTSPLRTRFVYHLSDLCKKCDPTEVELDNQIVTATQSNICDEDSATETCYTYDRNKCYTAVVPL VYGGETKMVETALTPDACYPD  9 matureQVQLVQSGAEVKKPGASVKVSCKASGYTFISYTMHWVR modified J-QAPGQGLEWMGYINPRSGYTHYNQKLKDKATLTADKSA chainSTAYMELSSLRSEDTAVYYCARSAYYDYDGFAYWGQGT sequence forLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDR V15JVTITCSASSSVSYMNWYQQKPGKAPKRLIYDTSKLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSSNPPTFGGGTKLEIKGGGGSGGGGSGGGGSQEDERIVLVDNKCKCARITSRIIRSSEDPNEDIVERNIRIIVPLNNRENISDPTSPLRTRFVYHLSDLCKKCDPTEVELDNQIVTATQSNICDEDSATETCYTYDRNKCYTAVVPLVYGGETKMVETALTPDACYPD 10 PrecursorMKNHLLFWGVLAVFIKAVHVKAQEDERIVLVDNKCKCA modified J-RITSRIIRSSEDPNEDIVERNIRIIVPLNNRENISDPTSPLRTR chainFVYHLSDLCKKCDPTEVELDNQIVTATQSNICDEDSATET sequence forCYTYDRNKCYTAVVPLVYGGETKMVETALTPDACYPDG J15VGGGSGGGGSGGGGSQVQLVQSGAEVKKPGASVKVSCKASGYTFISYTMHWVRQAPGQGLEWMGYINPRSGYTHYNQKLKDKATLTADKSASTAYMELSSLRSEDTAVYYCARSAYYDYDGFAYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQKPGKAPKRLIYDTSKLASGVPSRFSGSGSGTDFTLTISSLQPEDF ATYYCQQWSSNPPTFGGGTKLEIK 11mature QEDERIVLVDNKCKCARITSRIIRSSEDPNEDIVERNIRIIVP modified J-LNNRENISDPTSPLRTRFVYHLSDLCKKCDPTEVELDNQI chainVTATQSNICDEDSATETCYTYDRNKCYTAVVPLVYGGET sequence forKMVETALTPDACYPDGGGGSGGGGSGGGGSQVQLVQS J15VGAEVKKPGASVKVSCKASGYTFISYTMHWVRQAPGQGLEWMGYINPRSGYTHYNQKLKDKATLTADKSASTAYMELSSLRSEDTAVYYCARSAYYDYDGFAYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQKPGKAPKRLIYDTSKLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSSNPPTFGGGTKLEIK 12 (GGGGS)₃ GGGGSGGGGSGGGGSlinker 13 1.5.3 VH EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHPSYGSGSPNFDYWGQGTL VTVSS 14 1.5.3 VLDIVMTQTPLSSPVTLGQPASISCRSSQSLVYSDGNTYLSWLQQRPGQPPRLLIYKISNRFSGVPDRFSGSGAGTDFTLKISRVEAEDVGVYYCVQATQFPLTFGGGTKVEIK 15 ModifiedGSASAPTLFPLVSCENSPSDTSSVAVGCLAQDFLPDSITFS human IgMWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVM constantQGTDEHVVCKVQHPNGNKEKNVPLPVIAELPPKVSVFVP regionPRDGFFGNPRKSKLICQATGFSPRQIQVSWLREGKQVGSG L310AVTTDQVQAEAKESGPTTYKVTSTLTIKESDWLSQSMFTCRVDHRGLTFQQNASSMCVPDQDTAIRVFAIPPSFASIFLTKSTKLTCLVTDLTTYDSVTISWTRQNGEAVKTHTNISESHPNATFSAVGEASICEDDWNSGERFTCTVTHTDAPSPLKQTISRPKGVALHRPDVYLLPPAREQLNLRESATITCLVTGFSPADVFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEEWNTGETYTCVVAHEALPNRVTERTVDKSTGKP TLYNVSLVMSDTAGTCY 16 ModifiedGSASAPTLFPLVSCENSPSDTSSVAVGCLAQDFLPDSITFS human IgMWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVM constantQGTDEHVVCKVQHPNGNKEKNVPLPVIAELPPKVSVFVP regionPRDGFFGNPRKSKLICQATGFSPRQIQVSWLREGKQVGSG K315AVTTDQVQAEAKESGPTTYKVTSTLTIKESDWLSQSMFTCRVDHRGLTFQQNASSMCVPDQDTAIRVFAIPPSFASIFLTKSTKLTCLVTDLTTYDSVTISWTRQNGEAVKTHTNISESHPNATFSAVGEASICEDDWNSGERFTCTVTHTDLPSPLAQTISRPKGVALHRPDVYLLPPAREQLNLRESATITCLVTGFSPADVFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEEWNTGETYTCVVAHEALPNRVTERTVDKSTGKP TLYNVSLVMSDTAGTCY 17 ModifiedGSASAPTLFPLVSCENSPSDTSSVAVGCLAQDFLPDSITFS human IgMWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVM constantQGTDEHVVCKVQHPNGNKEKNVPLPVIAELPPKVSVFVP regionPRDGFFGNPRKSKLICQATGFSPRQIQVSWLREGKQVGSG L310A,VTTDQVQAEAKESGPTTYKVTSTLTIKESDWLSQSMFTC K315ARVDHRGLTFQQNASSMCVPDQDTAIRVFAIPPSFASIFLTKSTKLTCLVTDLTTYDSVTISWTRQNGEAVKTHTNISESHPNATFSAVGEASICEDDWNSGERFTCTVTHTDAPSPLAQTISRPKGVALHRPDVYLLPPAREQLNLRESATITCLVTGFSPADVFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEEWNTGETYTCVVAHEALPNRVTERTVDKSTGKP TLYNVSLVMSDTAGTCY 18 ModifiedGSASAPTLFPLVSCENSPSDTSSVAVGCLAQDFLPDSITFS human IgMWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVM constantQGTDEHVVCKVQHPNGNKEKNVPLPVIAELPPKVSVFVP regionPRDGFFGNPRKSKLICQATGFSPRQIQVSWLREGKQVGSG L310S,VTTDQVQAEAKESGPTTYKVTSTLTIKESDWLSQSMFTC K315SRVDHRGLTFQQNASSMCVPDQDTAIRVFAIPPSFASIFLTKSTKLTCLVTDLTTYDSVTISWTRQNGEAVKTHTNISESHPNATFSAVGEASICEDDWNSGERFTCTVTHTDSPSPLSQTISRPKGVALHRPDVYLLPPAREQLNLRESATITCLVTGFSPADVFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEEWNTGETYTCVVAHEALPNRVTERTVDKSTGKP TLYNVSLVMSDTAGTCY 19 ModifiedGSASAPTLFPLVSCENSPSDTSSVAVGCLAQDFLPDSITFS human IgMWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVM constantQGTDEHVVCKVQHPNGNKEKNVPLPVIAELPPKVSVFVP regionPRDGFFGNPRKSKLICQATGFSPRQIQVSWLREGKQVGSG L310A,VTTDQVQAEAKESGPTTYKVTSTLTIKESDWLSQSMFTC P311ARVDHRGLTFQQNASSMCVPDQDTAIRVFAIPPSFASIFLTKSTKLTCLVTDLTTYDSVTISWTRQNGEAVKTHTNISESHPNATFSAVGEASICEDDWNSGERFTCTVTHTDAASPLKQTISRPKGVALHRPDVYLLPPAREQLNLRESATITCLVTGFSPADVFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEEWNTGETYTCVVAHEALPNRVTERTVDKSTG KPTLYNVSLVMSDTAGTCY 20 ModifiedGSASAPTLFPLVSCENSPSDTSSVAVGCLAQDFLPDSITFS human IgMWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVM constantQGTDEHVVCKVQHPNGNKEKNVPLPVIAELPPKVSVFVP regionPRDGFFGNPRKSKLICQATGFSPRQIQVSWLREGKQVGSG L310A,VTTDQVQAEAKESGPTTYKVTSTLTIKESDWLSQSMFTC P313SRVDHRGLTFQQNASSMCVPDQDTAIRVFAIPPSFASIFLTKSTKLTCLVTDLTTYDSVTISWTRQNGEAVKTHTNISESHPNATFSAVGEASICEDDWNSGERFTCTVTHTDAPSSLKQTISRPKGVALHRPDVYLLPPAREQLNLRESATITCLVTGFSPADVFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEEWNTGETYTCVVAHEALPNRVTERTVDKSTGKP TLYNVSLVMSDTAGTCY 21 ModifiedGSASAPTLFPLVSCENSPSDTSSVAVGCLAQDFLPDSITFS human IgMWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVM constantQGTDEHVVCKVQHPNGNKEKNVPLPVIAELPPKVSVFVP regionPRDGFFGNPRKSKLICQATGFSPRQIQVSWLREGKQVGSG P311A,VTTDQVQAEAKESGPTTYKVTSTLTIKESDWLSQSMFTC K315ARVDHRGLTFQQNASSMCVPDQDTAIRVFAIPPSFASIFLTKSTKLTCLVTDLTTYDSVTISWTRQNGEAVKTHTNISESHPNATFSAVGEASICEDDWNSGERFTCTVTHTDLASPLAQTISRPKGVALHRPDVYLLPPAREQLNLRESATITCLVTGFSPADVFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEEWNTGETYTCVVAHEALPNRVTERTVDKSTG KPTLYNVSLVMSDTAGTCY 22 ModifiedGSASAPTLFPLVSCENSPSDTSSVAVGCLAQDFLPDSITFS human IgMWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVM constantQGTDEHVVCKVQHPNGNKEKNVPLPVIAELPPKVSVFVP regionPRDGFFGNPRKSKLICQATGFSPRQIQVSWLREGKQVGSG P313S,VTTDQVQAEAKESGPTTYKVTSTLTIKESDWLSQSMFTC K315ARVDHRGLTFQQNASSMCVPDQDTAIRVFAIPPSFASIFLTKSTKLTCLVTDLTTYDSVTISWTRQNGEAVKTHTNISESHPNATFSAVGEASICEDDWNSGERFTCTVTHTDLPSSLAQTISRPKGVALHRPDVYLLPPAREQLNLRESATITCLVTGFSPADVFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEEWNTGETYTCVVAHEALPNRVTERTVDKSTGKP TLYNVSLVMSDTAGTCY 23 ModifiedGSASAPTLFPLVSCENSPSDTSSVAVGCLAQDFLPDSITFS human IgMWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVM constantQGTDEHVVCKVQHPNGNKEKNVPLPVIAELPPKVSVFVP regionPRDGFFGNPRKSKLICQATGFSPRQIQVSWLREGKQVGSG L310DVTTDQVQAEAKESGPTTYKVTSTLTIKESDWLSQSMFTCRVDHRGLTFQQNASSMCVPDQDTAIRVFAIPPSFASIFLTKSTKLTCLVTDLTTYDSVTISWTRQNGEAVKTHTNISESHPNATFSAVGEASICEDDWNSGERFTCTVTHTDDPSPLKQTISRPKGVALHRPDVYLLPPAREQLNLRESATITCLVTGFSPADVFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEEWNTGETYTCVVAHEALPNRVTERTVDKSTGKP TLYNVSLVMSDTAGTCY 24 ModifiedGSASAPTLFPLVSCENSPSDTSSVAVGCLAQDFLPDSITFS human IgMWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVM constantQGTDEHVVCKVQHPNGNKEKNVPLPVIAELPPKVSVFVP regionPRDGFFGNPRKSKLICQATGFSPRQIQVSWLREGKQVGSG K315DVTTDQVQAEAKESGPTTYKVTSTLTIKESDWLSQSMFTCRVDHRGLTFQQNASSMCVPDQDTAIRVFAIPPSFASIFLTKSTKLTCLVTDLTTYDSVTISWTRQNGEAVKTHTNISESHPNATFSAVGEASICEDDWNSGERFTCTVTHTDLPSPLDQTISRPKGVALHRPDVYLLPPAREQLNLRESATITCLVTGFSPADVFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEEWNTGETYTCVVAHEALPNRVTERTVDKSTGKP TLYNVSLVMSDTAGTCY 25 ModifiedGSASAPTLFPLVSCENSPSDTSSVAVGCLAQDFLPDSITFS human IgMWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVM constantQGTDEHVVCKVQHPNGNKEKNVPLPVIAELPPKVSVFVP regionPRDGFFGNPRKSKLICQATGFSPRQIQVSWLREGKQVGSG K315QVTTDQVQAEAKESGPTTYKVTSTLTIKESDWLSQSMFTCRVDHRGLTFQQNASSMCVPDQDTAIRVFAIPPSFASIFLTKSTKLTCLVTDLTTYDSVTISWTRQNGEAVKTHTNISESHPNATFSAVGEASICEDDWNSGERFTCTVTHTDLPSPLQQTISRPKGVALHRPDVYLLPPAREQLNLRESATITCLVTGFSPADVFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEEWNTGETYTCVVAHEALPNRVTERTVDKSTGKP TLYNVSLVMSDTAGTCY

The breadth and scope of the present disclosure should not be limited byany of the above-described exemplary embodiments but should be definedonly in accordance with the following claims and their equivalents.

What is claimed is:
 1. A modified human IgM constant region comprisingone or more amino acid substitutions relative to a wild-type human IgMconstant region, wherein at least one amino acid substitution is at aposition in the Cμ3 domain ranging from T302 of SEQ ID NO: 1 to K322 ofSEQ ID NO: 1, and wherein a modified IgM antibody comprising themodified IgM constant region and a heavy chain variable region specificfor a target antigen exhibits reduced complement-dependent cytotoxicity(CDC) of cells expressing the target antigen relative to a correspondingwild-type human IgM antibody.
 2. The modified human IgM constant regionof claim 1, wherein the at least one amino acid substitution is at aminoacid T302, C303, T304, V305, T306, H307, T308, D309, L310, P311, S312,P313, L314, K315, Q316, T317, I318, S319, R320, P321, and/or K322 of SEQID NO:
 1. 3. The modified human IgM constant region of claim 2 whereinthe at least one amino acid substitution is at position L310 of SEQ IDNO: 1, position P311 of SEQ ID NO: 1, position P313 of SEQ ID NO: 1,position K315 of SEQ ID NO: 1, or any combination thereof.
 4. Themodified human IgM constant region of claim 3, wherein the amino acidsubstitution is at position L310 of SEQ ID NO:
 1. 5. The modified humanIgM constant region of claim 4, wherein L310 of SEQ ID NO: 1 issubstituted with alanine (L310A), serine (L310S), aspartic acid (L310D)or glycine (L310G).
 6. The modified human IgM constant region of claim5, wherein L310 of SEQ ID NO: 1 is substituted with alanine (L310A). 7.The modified human IgM constant region of claim 6, comprising SEQ ID NO:15.
 8. The modified human IgM constant region of claim 5, wherein L310of SEQ ID NO: 1 is substituted with aspartic acid (L310D).
 9. Themodified human IgM constant region of claim 8, comprising SEQ ID NO: 23.10. The modified human IgM constant region of claim 3, wherein the aminoacid substitution is at position P311 of SEQ ID NO:
 1. 11. The modifiedhuman IgM constant region of claim 10, wherein P311 of SEQ ID NO: 1 issubstituted with alanine (P311A), serine (P311S), or glycine (P311G).12. The modified human IgM constant region of claim 11, wherein P311 ofSEQ ID NO: 1 is substituted with alanine (P311A).
 13. The modified humanIgM constant region of claim 12, comprising SEQ ID NO:
 2. 14. Themodified human IgM constant region of claim 3, wherein the amino acidsubstitution is at position P313 of SEQ ID NO:
 1. 15. The modified humanIgM constant region of claim 14, wherein P313 of SEQ ID NO: 1 issubstituted with alanine (P313A), serine (P313S), or glycine (P313G).16. The modified human IgM constant region of claim 15, wherein P313 ofSEQ ID NO: 1 is substituted with serine (P313S).
 17. The modified humanIgM constant region of claim 16, comprising SEQ ID NO:
 3. 18. Themodified human IgM constant region of claim 3, wherein the amino acidsubstitution is at position K315 of SEQ ID NO:
 1. 19. The modified humanIgM constant region of claim 18, wherein K315 of SEQ ID NO: 1 issubstituted with alanine (K315A), serine (K315S), aspartic acid (K315D),glutamine (K315Q), or glycine (P313G).
 20. The modified human IgMconstant region of claim 19, wherein K315 of SEQ ID NO: 1 is substitutedwith alanine (K315A).
 21. The modified human IgM constant region ofclaim 20, comprising SEQ ID NO:
 16. 22. The modified human IgM constantregion of claim 19, wherein K315 of SEQ ID NO: 1 is substituted withaspartic acid (K315D).
 23. The modified human IgM constant region ofclaim 22, comprising SEQ ID NO:
 24. 24. The modified human IgM constantregion of claim 19, wherein K315 of SEQ ID NO: 1 is substituted withglutamine (K315Q).
 25. The modified human IgM constant region of claim24, comprising SEQ ID NO:
 25. 26. The modified human IgM constant regionof claim 3, comprising amino acid substitutions at positions P311 andP313 of SEQ ID NO:
 1. 27. The modified human IgM constant region ofclaim 26, wherein P311 of SEQ ID NO: 1 is substituted with alanine(P311A), serine (P311S), or glycine (P311G), and wherein P313 of SEQ IDNO: 1 is substituted with alanine (P313A), serine (P313S), or glycine(P313G).
 28. The modified human IgM constant region of claim 27, whereinP311 of SEQ ID NO: 1 is substituted with alanine (P311A) and P313 of SEQID NO: 1 is substituted with serine (P313S).
 29. The modified human IgMconstant region of claim 28, comprising SEQ ID NO:
 4. 30. The modifiedhuman IgM constant region of claim 3, comprising amino acidsubstitutions at positions L310 and K315 of SEQ ID NO: 1, wherein L310is substituted with alanine (L310A) or serine (L310S) and K315 issubstituted with alanine (K315A) or serine (K315S).
 31. The modifiedhuman IgM constant region of claim 30, comprising SEQ ID NO: 17 or SEQID NO:
 18. 32. The modified human IgM constant region of claim 3,comprising amino acid substitutions at positions L310 and P311 of SEQ IDNO: 1, wherein L310 is substituted with alanine (L310A) and P311 issubstituted with alanine (P311A).
 33. The modified human IgM constantregion of claim 32, comprising SEQ ID NO:
 19. 34. The modified human IgMconstant region of claim 3, comprising amino acid substitutions atpositions L310 and P313 of SEQ ID NO: 1, wherein L310 is substitutedwith alanine (L310A) and P313 is substituted with serine (P313S). 35.The modified human IgM constant region of claim 34, comprising SEQ IDNO:
 20. 36. The modified human IgM constant region of claim 3,comprising amino acid substitutions at positions P311 and K315 of SEQ IDNO: 1, wherein P311 is substituted with alanine (P311A) and K315 issubstituted with alanine (K315A).
 37. The modified human IgM constantregion of claim 36, comprising SEQ ID NO:
 21. 38. The modified human IgMconstant region of claim 3, comprising amino acid substitutions atpositions P313 and K315 of SEQ ID NO: 1, wherein P313 is substitutedwith serine (P313S) and K315 is substituted with alanine (K315A). 39.The modified human IgM constant region of claim 38, comprising SEQ IDNO:
 22. 40. The modified human IgM constant region of any one of claims1 to 39, wherein the maximum CDC activity achieved by a target-specificIgM antibody comprising the modified human IgM constant region in adose-response assay is reduced by at least 5%, 10%, 20%, 30%, 40%, 50%,60%, 70%, 80%, 90%, 95%, or 100% relative to a corresponding wild-typeIgM antibody identical except for the modified human IgM constantregion.
 41. The modified human IgM constant region of any one of claims1 to 39, wherein the antibody concentration of a target-specific IgMantibody comprising the modified human IgM constant region effecting 50%CDC activity (EC50) is increased by at least 2-fold, at least 5-fold, atleast 10-fold, at least 20-fold, and least 30-fold, at least 40-fold, atleast 50-fold, at least 60-fold, at least 70-fold, at least 80-fold, atleast 90-fold, or at least 100-fold relative to a correspondingwild-type IgM antibody identical except for the modified human IgMconstant region.
 42. A modified human IgM antibody comprising themodified human IgM constant region of any one of claims 1 to 41, and aheavy chain variable region (VH) situated amino terminal to the modifiedhuman IgM constant region, wherein the modified human IgM antibodyspecifically binds to a target antigen and exhibits reducedcomplement-dependent cytotoxicity (CDC) of cells expressing the targetantigen relative to a corresponding wild-type human IgM antibody. 43.The modified human IgM antibody of claim 42, which is a pentameric or ahexameric antibody comprising five or six bivalent IgM binding units,respectively, wherein each binding unit comprises two IgM heavy chainseach comprising a VH situated amino terminal to the modified human IgMconstant region, and two immunoglobulin light chains each comprising alight chain variable domain (VL) situated amino terminal to a humanimmunoglobulin light chain constant region.
 44. The modified human IgMantibody of claim 43, which is a pentameric, and further comprises aJ-chain, or functional fragment thereof, or a functional variantthereof.
 45. The modified human IgM antibody of claim 44, whereinJ-chain or fragment thereof comprises amino acids 23 to 158 of SEQ IDNO: 7 or a functional fragment thereof, or a functional variant thereof.46. The modified human IgM antibody of claim 44 or claim 45, wherein theJ-chain or fragment or variant thereof is a modified J-chain furthercomprising a heterologous polypeptide, wherein the heterologouspolypeptide is directly or indirectly fused to the J-chain or fragmentor variant thereof.
 47. The modified human IgM antibody of claim 46,wherein the heterologous polypeptide is fused to the J-chain or fragmentthereof via a peptide linker.
 48. The modified human IgM antibody ofclaim 47, wherein the peptide linker comprises at least 5 amino acids,but no more than 25 amino acids.
 49. The modified human IgM antibody ofclaim 48, wherein the peptide linker consists of GGGGSGGGGSGGGGS (SEQ IDNO: 12).
 50. The modified human IgM antibody of any one of claims 46 to49, wherein the heterologous polypeptide is fused to the N-terminus ofthe J-chain or fragment or variant thereof, the C-terminus of theJ-chain or fragment or variant thereof, or to both the N-terminus andC-terminus of the J-chain or fragment or variant thereof.
 51. Themodified human IgM antibody of any one of claims 46 to 50, wherein theheterologous polypeptide comprises a binding domain.
 52. The modifiedhuman IgM antibody of claim 51, wherein the binding domain of theheterologous polypeptide is an antibody or antigen-binding fragmentthereof.
 53. The modified human IgM antibody of claim 52, wherein theantigen-binding fragment comprises an Fab fragment, an Fab′ fragment, anF(ab′)2 fragment, an Fd fragment, an Fv fragment, a single-chain Fv(scFv) fragment, a disulfide-linked Fv (sdFv) fragment, or anycombination thereof.
 54. The modified human IgM antibody of claim 53,wherein the antigen-binding fragment is a scFv fragment.
 55. Themodified human IgM antibody of any one of claims 51 to 54 wherein theheterologous polypeptide can specifically bind to CD3ε.
 56. The modifiedhuman IgM antibody of claim 55, wherein the modified J-chain comprisesthe amino acid sequence SEQ ID NO: 9 (V15J) or SEQ ID NO: 11 (J15V). 57.The modified human IgM antibody of claim 56, wherein the modifiedJ-chain further comprises a signal peptide.
 58. The modified human IgMantibody of claim 57 wherein the modified J-chain comprises the aminoacid sequence SEQ ID NO: 8 (V15J) or SEQ ID NO: 10 (J15V).
 59. Themodified human IgM antibody of any one of claims 55 to 58, which candirect T-cell-mediated killing of a cell expressing the target antigenequivalent to that of a corresponding IgM antibody that is identical tothe modified IgM antibody except for the modified IgM constant region.60. The modified human IgM antibody of any one of claims 42 to 59,wherein the cell expressing the target antigen is a eukaryotic cell. 61.A polynucleotide comprising a nucleic acid sequence that encodes themodified human IgM constant region of any one of claims 1 to 40, or aheavy chain polypeptide subunit of the modified human IgM antibody ofany one of claims 42 to
 59. 62. A composition comprising thepolynucleotide of claim
 61. 63. The composition of claim 62, furthercomprising a nucleic acid sequence that encodes a light chainpolypeptide subunit.
 64. The composition of claim 63, wherein the lightchain polypeptide subunit comprises a human antibody light chainconstant region or fragment thereof fused to the C-terminal end of a VL.65. The composition of claim 63 or claim 64, wherein the nucleic acidsequence encoding the heavy chain polypeptide subunit and the nucleicacid sequence encoding the light chain polypeptide subunit are onseparate vectors.
 66. The composition of claim 63 or claim 64, whereinthe nucleic acid sequence encoding the heavy chain polypeptide subunitand the nucleic acid sequence encoding the light chain polypeptidesubunit are on a single vector.
 67. The composition of any one of claims62 to 66, further comprising a nucleic acid sequence that encodes aJ-chain, or functional fragment thereof, or a functional variantthereof.
 68. The composition of claim 67, wherein the J-chain orfragment thereof is a modified J-chain that further comprises aheterologous polypeptide, wherein the heterologous polypeptide isdirectly or indirectly fused to the J-chain or fragment thereof.
 69. Thecomposition of claim 67 or claim 68, wherein the nucleic acid sequenceencoding the heavy chain polypeptide subunit, the nucleic acid sequenceencoding the light chain polypeptide subunit, and the nucleic acidsequence encoding the J-chain are on a single vector.
 70. Thecomposition of claim 67 or claim 68, wherein the nucleic acid sequenceencoding the heavy chain polypeptide subunit, the nucleic acid sequenceencoding the light chain polypeptide subunit, and the nucleic acidsequence encoding the J-chain are each on separate vectors.
 71. A vectorof claim 66 or claim
 69. 72. The vectors of claim 65 or claim
 70. 73. Ahost cell comprising the polynucleotide of claim 61, the composition ofany one of claims 62 to 70, or the vector or vectors of claim 71 orclaim 72, wherein the host cell can express the modified human IgMconstant region of any one of claims 1 to 40, or the modified human IgMantibody of any one of claims 42 to 59 or a functional fragment thereof.74. A method of producing the modified human IgM constant region of anyone of claims 1 to 40, or the modified human IgM antibody of any one ofclaims 42 to 60, comprising culturing the host cell of claim 73, andrecovering the constant region or antibody.